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CHAPTER I 
INTRODUCTION 
Adipocytes are highly specialized cells that play a central role in systemic 
energy homeostasis. These cells have evolved complex biochemical machinery 
and transport systems that allow them to store energy in the form of 
triglycerides in times of nutritional abundance, and release this energy in times 
of nutritional deprivation. Intensive studies of adipocyte biochemistry have 
revealed considerable information about the hormonal control of carbohydrate 
and lipid metabolism, particularly the hormone-regulated enzymes involved in 
these processes (1). Despite that, our understanding of how adipocytes 
differentiate and the precise role these cells play in maintaining blood glucose 
homeostasis is still incomplete. 
When the function of adipocytes is altered, a number of disease states occur 
including cachexia, lipodystrophy, obesities, and diabetes (2-4). In the latter 
state, insufficient disposal of glucose by adipose and muscle leads to elevated 
blood glucose levels. This hyperglycemic state can be corrected in diabetic 
patients by treatment with oral hypoglycemic agents which have been mostly 
shown to increase glucose uptake by stimulating insulin release from the 
pancreas (5). A more recent and favorable approach is to use insulin-
sensitizers, agents that act to enhance sensitivity of target tissues to insulin. 
Our preliminary studies with pioglitazone, a novel hypoglycemic agent which 
presumably acts to enhance insulin sensitivity of target tissues ( 6), suggested 
that this agent might act to accelerate adipocyte differentiation. 
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Adipocyte cells express a program of proteins quite distinctive from other 
cell types, thus determining the ability of these cells to carry out their 
specialized function in energy balance (7-10). It is known that the acquisition of 
specialized phenotype, which characterizes the latter stages of differentiation of 
cells and tissues, is associated with the coordinate expression of new genes and 
the concomitant loss of expression of genes specific to less-differentiated cells. 
We therefore, sought to fully investigate the effect of pioglitazone on cell 
differentiation to determine how such an effect might contribute to the action of 
pioglitazone to regulate cellular glucose uptake. 
CHAPTER II 
REVIEW OF REI.ATED LITERATURE 
Glucose Transpoit in theAdipocyte 
Adipose tissue serves as the primary energy reservoir in mammals, converting 
excess dietary glucose and fatty acids into triglycerides. When dietary nutrients 
are lacking, these triglycerides are hydrolyzed to glycerol and fatty acids and 
released into the systemic circulation. It is estimated that adipose tissue 
accounts quantitatively for 10-30% of whole-body glucose metabolism (11). 
The transport of glucose into muscle and adipose tissue, the rate limiting 
step of glucose utilization, is mediated by integral membrane carrier proteins 
belonging to a family of facilitated glucose transporters (12, 13). These proteins 
transport glucose down its concentration gradient by facilitative diffusion, a 
passive, energy independent process that is tightly regulated in adipocytes by 
insulin and counterregulatory factors (1). 
Stimulatory actions of insulin on ~lucose transport 
The process by which insulin increases glucose transport in peripheral tissues 
has been studied extensively. Insulin actions are initiated by binding of the 
hormone to a specific membrane receptor that possesses an intrinsic protein 
kinase activity localized to its transmembrane B-subunit (14). 
Autophosphorylation of the receptor on tyrosine residues results in receptor 
3 
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activation with subsequent stimulation of glucose transport (15,16). At least two 
members of the glucose transporter family (GLUTl and GLUT4) are 
expressed in both adipose and muscle, tissues where glucose uptake is sensitive 
to regulation by insulin (17). It was demonstrated that adipocytes contain a 
large intracellular pool of glucose transporters. Insulin stimulates glucose 
uptake primarily by induction of a rapid translocation of pre-existing 
transporters from an inner membrane fraction to the plasma membrane 
resulting in as much as a 100-fold increase in the Vmax for transport (18,19). 
Although both GLUTl and GLUT4 transporters are capable of translocation, 
the GLUTl protein accounts for about 10-fold fewer glucose transporters than 
GLUT4 protein in primary adipocytes, and these GLUTl transporters are 
mostly localized in the plasma membrane. Thus, the effect of insulin appeared 
to be predominantly on the GLUT4 protein (20,21). Since quantitative 
comparisons revealed a significant discrepancy between the transport activity 
and the number of transporters in basal and insulin-stimulated cells, it was 
suggested that other mechanisms such as changes of the transporter intrinsic 
activity also contribute to insulin action (19,22-24). Indeed, qualitative 
alternations of the glucose transporters were reported, including GLUT4 
phosphorylation in adipocytes treated with .B-adrenergic agonists (25), or with 
agents that increased intracellular calcium levels (26). In addition to these 
acute effects, prolonged insulin treatment further regulated transport activity by 
a process requiring ongoing protein synthesis that may involve increased glucose 
transporter gene expression (17,27). 
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Inhibitmy actions of counterregulatmy factors on glucose transport 
The actions of insulin are opposed by several counterregulatory factors 
including hormones, neurotransmitters, and metabolic substrates (2,28). 
Glucagon, the most potent counterregulatory hormone, acts mainly on liver, but 
it does not affect peripheral glucose metabolism (1). In adipocytes, it was 
shown that stimulators of lipolysis are inhibitors of insulin-stimulated glucose 
oxidation and by inference, inhibitors of glucose transport (29). Conversely, 
antilipolytic agents exert an opposite effect, and produce a moderate 
augmentation of the insulin-stimulated transport activity (29). In rat adipocyte 
cells, ligands such as catecholamines stimulate adenylate cyclase leading to 
elevated cellular cAMP levels and inhibition of insulin-stimulated glucose 
transport activity (30,31). Similarly, the adenylate cyclase inhibitors such as 
prostaglandin E 1· nicotinic acid, and non-metabolized adenosine analogues 
prevent or reverse this inhibition (32). The inhibitory effect of catecholamines 
in adipocytes reflects both a shift of the concentration-response curve to higher 
insulin concentrations and a marked reduction of the maximal effect on insulin. 
The first component may be attributed to inhibition of the insulin receptor 
kinase, whereas the latter effect appears to reflect a change in intrinsic activity 
of glucose transporters. In addition, the insulin-induced subcellular 
translocation of glucose transporters is decreased in cells that have been 
exposed to ambient levels of cAMP. In contrast to these findings, activation of 
the lipolytic system in human fat cells at the levels of adrenoreceptors, 
adenylate cyclase, or protein kinase appears to be associated with an 
acceleration of the glucose transport rate (29). This indicates that there are 
important species differences in the regulation of adipocyte glucose transport at 
least regarding the effect of lipolytic agents. On the other hand, the action of 
antilipolytic agents (ie. insulin and adenylate cyclase inhibitors) appear to be 
similar in human and rat fat cells (29). 
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Two additional hormones that are known to modulate the regulation of 
glucose transport by insulin in the rat adipose cells are the glucocorticoids (33) 
and growth hormone (34 ). It has been established that glucocorticoids, 
specifically the analogue dexamethasone, induce a decrease in both basal and 
insulin-stimulated glucose transport activity (35) either by accelerating 
degradation of glucose transporters present in the plasma membrane and/ or by 
inducing a redistribution of glucose transporters in favor of the intracellular 
pool. An excess of circulating growth hormone in both rat and man appears to 
correlate with insulin resistance and elevated blood glucose levels, while growth 
hormone-deficient conditions are associated with an increased response to 
insulin (19); the cellular mechanism underlying this phenomenon has not been 
established. 
Forskolin, an agent known to elevate cellular cAMP levels, is another 
powerful inhibitor of glucose transport in adipocytes; this agent initiates 
adenylate cyclase stimulation and inhibit glucose transport at different sites 
including direct binding to glucose transporters (36). Inhibitors of nucleoside 
transport (methylxanthines) are also potent inhibitors of glucose transport in rat 
adipocytes, apparently by direct interaction with the glucose transporters (36). 
Finally, metabolic substrates such as glucose and amino acids have profound 
effects on modulating insulin's stimulatory actions on glucose uptake in primary 
cultured adipocytes (37). Specifically, circulating levels of glucose and amino 
acids modulate cellular metabolism through two independent, but integrated, 
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control systems. The first system is the classical substrate-pancreatic axis, in 
which glucose and amino acids act as potent secretagogues for the release of 
insulin. The second control system acts in tandem with the first by enabling 
insulin target tissues to continuously monitor circulating levels of glucose and 
amino acids, thereby modulating cellular responsiveness at distinct postreceptor 
sites within the insulin action pathways. It was recently discovered in the rat 
primary cultured adipocytes that routing of incoming glucose through the 
hexosamine biosynthesis pathway leads over several hours to a refractory state 
in which the ability of insulin to stimulate glucose uptake is severely impaired- a 
state known as insulin resistance. Glutamine:fructose-6-phosphate 
amidotransferase was also found to play a central role in the development of 
insulin resistance, as this enzyme catalyzes the first and limiting step in the 
formation of hexosamine products (37). 
Adipocyte Differentiation 
Adipocyte differentiation occurs through a process in which preadipocyte 
cells, ie. fibroblasts cells populating the future adipose tissues, are 
reprogrammed to stop dividing and start expressing properties and functions of 
adipocytes. While the reprogramming process generating committed cells takes 
place only in embryonic life, the differentiation of these committed cells can 
take place at any time, even in adult life (38). 
Models for studying the adipocyte 
Since primary adipocytes isolated from adipose tissue only remain viable a 
few hours, the ability to study adipocyte differentiation, gene expression, and 
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morphological and biochemical changes during the process, was greatly 
facilitated by the isolation of preadipocyte cell lines that could be induced to 
differentiate into adipocytes in culture. Studies showed that Swiss 3T3 
fibroblasts were able to differentiate spontaneously to adipocytes in culture 
(39). This process took 2-4 weeks, and the percentage of differentiated cells 
varied from culture to culture. From these established fibroblasts, Green and 
Kehinde isolated clonal sublines (e.g. 3T3-L1 and 3T3-F442A) that could 
differentiate to adipocytes at high frequency (40,41). Also established were 
clonal cell lines ob17 and HG-Fu rising from differentiated adipocytes from the 
epididymal fat pad of adult ob/ ob mouse, PFC6 from the stromal-vascular 
fraction of epididymal fat pad which contains preadipocyte cells, and the ST13 
cell line arising from the parental line ST that was itself established from a 
mammary carcinoma of the ddN mice ( 42). 
Such differentiation was studied extensively and was found in many respects 
to resemble the in vivo development of adipocytes from stromal vascular cells 
(the adipose precursor cells). In these cell lines, the preadipocytes are 
fibroblast-like cells. Once the cell growth was arrested by reaching confluence 
in culture, the cells exhibited morphological characteristics of adipocytes and 
accumulated lipid droplets. At the same time, the cells developed enzymatic 
activities related to fatty acid and triglyceride synthesis ( 43), and acquired 
sensitivities to hormones that are important in the regulation of fat and 
carbohydrate metabolism ( 44,45). 
Under ordinary conditions, only a minority of the cells undergo adipose 
differentiation. There is therefore a marked heterogeneity in the predisposition 
for differentiation. This property of preadipose cells ensures that some cells are 
9 
retained in developing tissue for later recruitment to formation of more adipose 
cells (38). 
Mitogenic response of differentiating cells and its role in clonal selection 
It is known that for preadipocytes, as well as other cell types, growth arrest is 
a prerequisite for the induction of the differentiation program ( 46). 
Paradoxically, among the earliest events taking place in adipocyte 
differentiation was a mitogenic response in susceptible cells so that they 
appeared later in clusters ( 46-48). Studies have shown that after stimulation 
with adipogenic serum, 3T3-F442A preadipocyte cells underwent a mitogenic 
response characterized by a burst in DNA replication and cell division before 
they expressed the differentiated state. In addition, it was demonstrated that 
DNA synthesis was required for adipose differentiation of cultured cells ( 48). 
Growth arrest at the Gi/S boundary triggered the activation of early genes. 
But the expression of late markers, which led to terminal differentiation and 
accumulation of neutral lipids, took place after a limited number of mitoses of 
early-marker-expressing cells. The mitogenic proliferation of those cells 
responding to the adipogenic factor led to a selective increase in their progeny, 
all of which formed adipocytes ( 49). This form of mitogenic response occurred 
only in the early stages of adipocyte differentiation since fully differentiated 
cells do not divide (38). 
Morpholo~cal changes during adipocyte differentiation 
Differentiation of preadipocytes into adipocytes is accompanied by changes 
in their morphological appearance. Preadipocytes appear as extended irregular 
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fibroblast-like cells. Upon differentiation, such cells enlarge, acquire a 
spherical shape, and later accumulate lipid droplets in their cytoplasm. Small 
lipid globules may ultimately fuse into a few or a single fat globule. It was 
shown that the change in cell shape during differentiation was independent of 
lipid accumulation. This was demonstrated by culturing cells in biotin-deficient 
medium wherein the cells were unable to synthesize fatty acids and were 
therefore unable to accumulate triglycerides (50). Nevertheless, these cells 
acquired a spherical shape, suggesting that the morphological changes were part 
of the differentiation program and not simply the result of triglyceride 
accumulation in their cytoplasm. Measured changes of the synthesis and 
assembly of cytoskeletal proteins during differentiation were consistent with 
that concept. Undifferentiated 3T3-Ll cells, for instance, contained actin-like 
stress fibers and synthesized actin as well as bundles of intermediate filaments 
(51). Upon differentiation, both structures disappeared and cell content of 
actin and tubulin decreased several fold. A decrease in the net production of 
extracellular matrix components, particularly proteoglycans typical of fibrous 
connective tissue, was also described (52). 
Enzymatic changes and triglyceride accumulation during differentiation 
During adipocyte differentiation, there is a large increase in the synthesis of 
more than 50 cellular proteins (7) and a 50- to 100-fold increase in the cellular 
triglyceride content ( 40). Triglyceride accumulation can be affected by different 
factors, which make it an extremely variable feature. Insulin, methyl isobutyl 
xanthine and dexamethasone were shown to increase, while B-adrenergic 
catecholamines decrease, triglyceride accumulation (38,40). A coordinate rise 
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in most of the enzymes of de novo fatty acid synthesis (53) and of some of the 
enzymes of the triglyceride synthesis pathway was observed ( 43,54 ). This greatly 
enhanced the ability of cells to synthesize fatty acids, to take up exogenous fatty 
acids, and to esterify fatty acids obtained from either source (55,56); all of these 
actions resulted from increased expression of appropriate regulatory enzymes. 
Chanies in receptor levels and hormonal responses of differentiated cells 
Although preadipocyte cells in culture possess cell surface receptors for 
insulin, no metabolic responses to insulin are observed in these cells. Upon 
differentiation, there is a dramatic increase in the insulin-binding capacity (57) 
which is primarily accounted for by a change in receptor number resulting from 
a parallel rise in the rate of insulin receptor synthesis ( 44,45). These changes in 
receptor levels were accompanied by increases in glucose metabolism and 
insulin responsiveness (58-60), the latter of which was shown to be due to a 
decreased basal glucose transport rate rather than an increased maximal rate 
after stimulation by insulin. The coupling between insulin binding and the 
biological response was greatly enhanced, as was the coupling to adenylate 
cyclase in response to ACTH and B-adrenergic catecholamines (7,38,61). In 
addition, adipocytes differentiated from different cell lines manifest properties 
similar to adipocytes isolated from adipose tissue, including responsiveness to 
lipolytic hormones, elevated basal glucose transport activity after prolonged 
exposure to insulin (62), and resistance to stimulation by insulin after chronic 
exposure to insulin, glucocorticoids (7), and growth hormone (63). 
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Factors That Regulate Adipocyte Diffeientiation 
The specific factors that regulate adipocyte differentiation and the 
mechanisms by which such factors act have not been revealed. Initially, cells 
have to be committed for differentiation. Evidence of the process whereby 
committed cells were generated resulted from the experiment in which cells of 
the nondifferentiating mouse 3T3-C2 line were transfected with DNA from 
uninduced 3T3-F442A preadipocytes or from human fat tissue (64). Such 
transfection permitted recovery of 3T3-C2 transfectants that differentiate into 
adipocytes in the presence of insulin, thus implicating the presence of 
transregulatory gene or genes in committed 3T3-F442A or human fat cell DNA 
that was sufficient to commit 3T3-C2 cells to adipocyte differentiation. In order 
for preadipocytes to subsequently differentiate, the cells must reach a confluent 
resting state that is followed by a mitogenic response ( 46). However, growth 
arrest itself was not sufficient to induce differentiation, since agents such as 
sodium pyruvate that cause growth arrest only accelerated differentiation in the 
presence of other adipogenic factors (65). Extracellular and regulatory 
adipogenic serum factors of different species were thus shown to be required for 
the process which could be divided into early and late stages. Fetal calf serum 
is by far the most effective serum used for cellular differentiation (66). In 
addition, bovine pituitary extracts showed an adipogenic activity that was at 
least three orders of magnitude higher in pituitary than in fetal calf serum. Only 
growth hormone was found to promote preadipocyte differentiation, while 
adipogenic activity was not associated with other pituitary polypeptides (67). A 
number of studies have implicated both growth hormone (GH) and insulin like 
growth factor-I (IGF-I) (68-70) during the early events of adipose 
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differentiation. Growth hormone is suggested to promote preadipocyte 
differentiation, generating committed precursors sensitive to the proliferative 
mitogenic action of IGF-1. The late events of the adipose pathway represent the 
terminal differentiation of the committed cells, and require the presence of 
modulating signals mainly elicited by physiological concentrations of insulin 
(43,47). Thus, it seems that a combination of mitogenic-adipogenic signals is 
required to trigger terminal differentiation of preadipose cells. The 
requirement for serum, however, is not absolute since 1246 cells were able to 
differentiate in a serum-free medium containing insulin, transferrin and 
fibroblast growth factor (7). Another study demonstrated a complete adipose 
differentiation of 3T3-L 1 cells in a chemically defined culture system 
supplemented with insulin, glucocorticoids, and factors that increase the cAMP 
content of the cells (71), and a third study showed 3T3-Ll differentiation by 
IGF-1 and insulin in a serum-free culture system (69). Although the expression 
of the adipocyte phenotype has been shown to be under the control of lipogenic 
hormones, especially insulin, other factors including indomethasone ( 60), 
prostaglandin F2a and 1-methyl-3-isobutylxanthine (72), dexamethasome 
(65,73), triiodothyronine (74), glucocorticoids (75), and other factors such as 
RU38486, a potent glucocorticoid and progestin antagonist(76), sodium 
pyruvate in combination with insulin or dexamethasone ( 65), the antidiabetic 
agent AD4743 (77,78), or the expression of transfected ras oncogenes (79), have 
all been variously shown to accelerate adipose differentiation in adipocyte 
models 
On the other hand, adipocyte cells may lose their differentiated function and 
exhibit properties of less differentiated cells in response to modulation by 
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environmental influences. Cultured TAl adipocytes treated with tumor 
necrosis factor alpha (TNF a) for instance, lose intracytoplasmic lipid and, over 
a period of days, come to resemble their predifferentiated progenitors (80). 
Within hours of TNF addition to adipocytes, mRNAs for genes whose 
expression is augmented during adipogenesis decreased to predifferentiated 
levels. Transforming growth factor-B also caused a rapid decrease in expression 
of adipose genes when added to fully differentiated cells (80,81 ), while 
interferon completely inhibited the differentiation of 3T3-Ll mouse fibroblasts 
into adipocytes (82). 
Mechanisms Underlying Activity Changes During DHerentiation 
The acquisition by adipose precursor cells of the morphological and 
biochemical characteristics of mature adipocytes is mediated by extensive 
reprogramming of gene expression resulting in alternations in the abundance of 
several mRNAs and proteins, and appearance of many new adipocyte-specific 
mRNAs and proteins. These changes are brought about by both transcriptional 
regulation at the level of the gene and post-transcriptional regulation between 
the RNA and the protein product (83-85). 
Expression of adipocyte-specific genes 
Electrophoretic studies of preadipocyte and adipocyte proteins indicated that 
there were major quantitative changes in at least 100 protein species and that 
40% of the soluble adipocyte proteins represented newly produced material 
(83,86) including enzymes involved in fatty acid and triglyceride synthesis, such 
as glycerol phosphate dehydrogenase (GPDH), fatty acid synthetase, 
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phosphoenol pyruvate carboxykinase, and lipoprotein lipase (7,56). Adipocyte 
differentiation was later shown to be associated with the coordinate expression 
of new genes and the concomitant loss of expression of genes specific to less-
differentiated cells (8-10,73). Subsequently, new and potentially important gene 
products of the adipocyte were identified by isolating cDNA clones 
corresponding to mRNAs that are specifically induced during adipocyte 
differentiation (84,85). Included are the cDNA clones encoding GPDH, a key 
enzyme in triglyceride synthesis which provides the glycerolphosphate backbone 
for acylation and its protein accounts for about 2% of the soluble protein in the 
adipose 3T3 cells, the adipocyte fatty acid-binding protein, aP2, that accounts 
for about 6% of soluble protein in the adipose cells, and the adipocyte serine 
protease homolog, adipsin, that accounts for about 5% of the soluble protein of 
adipose cells (85). The following section will discuss some of these genes, which 
are also known to be involved in energy metabolism. 
The aP2 gene 
The gene encodes an adipocyte homologue of myelin P2. This protein 
accounts for about 6% of adipocyte soluble proteins and has sequence 
homology to a class of fatty acid-binding proteins that includes liver fatty acid 
binding protein, intestinal heart fatty acid-binding protein and cellular retinoic 
acid-binding protein (87,88). The precise function of this putative lipid carrier 
protein is unknown, although it was found to be a cellular target for 
phosphorylation by the insulin receptor tyrosine kinase, and may thus be 
considered a potential mediator of insulin actions (89-91). The abundance of 
aP2 mRNA is increased by a factor of at least 100 during adipocyte 
differentiation (92). 
The adipsin gene 
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This gene encodes an adipocyte-specific serine protease homolog with 
complement factor D activity, formerly called 28k, that is synthesized by 
adipocytes and secreted into the blood stream (93-95). Its protein accounts for 
about 5% of the adipocyte soluble proteins. The expression of this gene was 
found to be quantitatively altered in certain models of obesity and diabetes (96-
98). Adipsin mRNA abundance is increased in adipose tissue during fasting in 
normal rats and in diabetes due to streptozotocin-induced insulin deficiency, but 
its mRNA abundance is decreased during the continuous infusion of glucose, 
which induces a hyperglycemic, hyperinsulinemic state that is accompanied by 
an increased adipose mass. Adipsin mRNA expression is also suppressed 
( > 100-fold) in two strains of genetically obese mice (dbl db and obi ob), and in 
obesity chemically induced by injection of monosodium glutamate into newborn 
mice. Circulating adipsin protein is correspondingly decreased in these animal 
models of obesity (98). 
Adipsin mRNA has also been shown to increase over 100-fold during 
differentiation of 3T3-preadipocytes (85,99). Studies have shown that insulin 
markedly increases adipsin secretion and mRNA levels during differentiation, 
presumably due to the ability of insulin to stimulate differentiation (100). This 
is in contrast with the finding of another study in which cells were differentiated 
in serum deprived-medium. These cells already exhibit, at day 1, a maximal 
amount of mRNA encoding for adipsin, which is tenfold decreased by the 
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presence of insulin (73). Both studies however, demonstrated negative effects 
of insulin on the abundance of adipsin mRNA and secretion in mature 
adipocyte cells. These findings indicate that adipsin appears to be an early 
marker of adipocyte differentiation, and its gene expression is increased during 
differentiation, but is dramatically down-regulated by the presence of insulin, 
especially after differentiation (73, 100). 
The insulin receptor gene 
This gene encodes the insulin receptor which mediates actions of insulin in 
target cells, presumably through the activation of the receptor tyrosine kinase 
(15, 101). Although insulin receptor is a housekeeping protein that is essential 
for cell growth and is usually synthesized at low levels in all cells, there are 
increased numbers of insulin receptors in major target tissues for insulin such as 
liver, muscle, and adipocytes. In addition, the number of insulin receptors 
decreases considerably under certain conditions, ie., chronic exposure of cells to 
insulin leads to a net loss of receptors from cell surface (down-regulation) by 
decreasing biosynthesis and accelerating degradation (58). In contrast, 
differentiation of 3T3-preadipocytes leads to a 10- to 20-fold increase in the 
number of insulin receptors on the cell surface, and this change is paralleled by 
a 10-fold increase in insulin receptor mRNA transcripts of two sizes (57,59, 102). 
Prolonged incubation of 3T3-L 1 differentiated adipocytes with insulin however, 
does not induce hormone-mediated down-regulation of the receptor ( 44 ). 
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Glucose transporter genes 
Glucose uptake across plasma membrane of insulin-sensitive tissues (heart, 
skeletal muscle and adipose) is carried out mainly by means of two transporters 
(20) belonging to a family of at least five tissue-specific facilitated-diffusion 
proteins (12,13,103-105). GLUT4 is an insulin-responsive glucose transporter 
expressed exclusively in fat and muscle (106); GLUTl is a transporter for basal 
uptake of glucose that is expressed ubiquitously in most tissues. The rate of 
glucose uptake is subject to both short-term and long-term regulation. It has 
been shown that insulin acutely, ie. within minutes, increases glucose uptake 10-
to 20-fold via the redistribution of glucose transporters from an intracellular 
pool to the plasma membrane (20, 107). After hours of treatment with insulin, 
there is a further increase in glucose uptake, which requires ongoing protein 
synthesis and may be mediated by an increase in glucose transporter gene 
expression (108). Other examples of long-term alternations in the 
responsiveness of glucose uptake to insulin include the fasted and diabetic 
states, both of which are associated with a decrease in GLUT4 mRNA and 
protein (109), and the differentiation of preadipocyte cells. It was demonstrated 
that undifferentiated 3T3-Ll and 3T3-F442A preadipocytes express only 
GLUTl transporter mainly on the cell surface, and are unresponsive to insulin 
(110). Upon differentiation, a large intracellular pool of glucose transporters is 
formed by redistribution of GLUTl and by addition of newly synthesized 
GLUTl and GLUT4 transporter into this pool (61,111), contributing to the 
development of insulin sensitivity in the differentiated cells (61). Once 
differentiated, 3T3 adipocytes display properties similar to adipocytes from fat 
tissue with regard to short and long term regulatory effects on glucose transport. 
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Such cells respond to acute insulin treatment with increases in glucose transport 
above basal levels (61). Both GLUTl and GLUT4 appeared to be hormone-
sensitive, since in differentiated cells insulin gave rise to transporter 
translocation from the intracellular compartment to the plasma membrane. 
Chronic-insulin treatment has been shown to produce an increase in the mRNA 
and total protein for GLUTl (108). The expression of GLUTl is associated 
with an increase in basal glucose uptake, but not in the insulin-stimulated 
increase in 2-deoxyglucose uptake rates by 3T3-L 1 fibroblasts and adipocytes 
(112). However, no change was observed in the total cellular mRNA and 
protein for GLUT4, although availability of GLUT4 at the cell surface was 
down-regulated to half the level found in the acute treatment (62). 
Differentiated 3T3 adipocytes, however, differ from those cells isolated from fat 
tissue with regard to the relative abundance of their glucose transporter 
isoforms. GLUT4 protein in fat tissue adipocytes is expressed at a considerably 
higher levels than is GLUTl protein. This is reversed in 3T3-Ll adipocytes 
where the relative amount is 4 to 1 for GLUTl and GLUT4, respectively (21). 
These observations indicate that the translocation of GLUT4 could largely 
account for the insulin effect on transport rate, as the case in fat tissue, only if 
the intrinsic activity of GLUT4 is much higher than that of GLUTl. 
Reirnlation of adipocyte gene expression 
The observed coordinate changes in the expression of a group of genes 
during differentiation has led to intensive investigation of the mechanisms 
underlying such processes. Run-on transcription activity by isolated nuclei 
revealed that the large increases in abundance of several mRNAs were 
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accompanied by marked rises in their nuclear transcription rates. This was 
particularly shown for highly regulated mRNAs (20- to 100- fold increase in the 
steady-state mRNA levels) such as those encoding aP2 (8,9), adipsin (9), 
glycerol phosphate dehydrogenase (9), and phosphoenolpyruvate carboxykinase 
(56), thus suggesting that an increased rate of specific transcription is primarily 
responsible for the accumulation of these mRNAs during differentiation. The 
activation of transcription of those adipocyte-specific genes was not synchronous 
indicating that the temporal differences in the appearance of different adipocyte 
mRNAs probably result from differences in the times of activation of 
transcription (9). However, no changes in the rates of transcription was 
observed for moderately regulated mRNAs (2- to 4- fold increase or decrease in 
their steady state mRNA levels) such as fructose-1,6-bisphosphate aldolase, 
actin and tubulin mRNAs (8). These same studies indicated that post-
transcriptional regulatory mechanisms were operative during differentiation of 
adipose precursor cells. This was inferred from the poor correlation between 
relative steady-state mRNA levels and transcription rates for some of the genes. 
Steady-state levels of mRNAs for aP2 and adipsin for instance, were much 
greater than would be expected from their relative transcription rates, 
indicating a possible role for regulation of mRNA stability (84 ). 
A search for candidate transcription factor(s) or regulatory sequence 
element(s) that could be involved in coordinating those observed changes in 
gene expression revealed several different possible mechanisms. DNase I 
footprinting for promoters of several adipocyte-specific genes using nuclear 
extracts from undifferentiated and differentiated 3T3-L 1 cells revealed that a 
differentiation-specific nuclear factor binds to specific regions relative to the 
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start site of transcription. This transcription factor was later shown to be the 
CCAAT/enhancer binding protein (C/EBP), the mRNA of which was found at 
high levels in tissues that metabolize lipids and cholestrol-related compounds, 
mainly liver and adipocytes (113,114), and its expression was limited to fully 
differentiated fat and liver cells. Transient cotransfection studies revealed that 
C/EBP binds to, and trans-activates promoters of several differentiation-
dependent genes, including GLUT4 (115), aP2, stearoyl-CoA desaturase 1 
(116,117), and insulin receptor (118) gene promoters, as well as the C/EBP 
promoter itself (119). Hence, it was proposed that C/EBP may play a key role 
in coordinating transcription of genes involved in energy metabolism during 
differentiation of adipocytes (120,121). Consistent with this proposed role is the 
observation that an increase in the rate of C/EBP transcription precedes that of 
several adipose-specific genes whose promoters are transactivated by C/EBP 
(122). 
On the other hand, a comparison of the DNA sequences 5' to the 
transcription start site of several differentiation-dependent genes allowed 
characterization of sequence homologies which might represent core elements 
involved in differentiation-dependent transcription. Two such elements, 
designated fat-specific elements FSE 1 and 2, were described (92, 123). These 
elements are FSEl, a 14-base sequence present in multiple nonidentical copies 
in the 5' flanking region of GPDH, aP2, and adipsin, and FSE2, a 21-base 
sequence present in a single copy in the 5' flanking regions of only the GPDH 
and aP2 genes that acts as a negative regulator in preadipocytes (92, 123). The 
gel mobility shift assay indicated that Fos, a nuclear phosphoprotein encoded by 
the c.f os proto-oncogene, is a major component of a protein complex that binds 
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the FSE2 element in a differentiation-dependent manner (124). This was 
demonstrated by the ability of antibodies to F os to disrupt specific binding of 
factors to the FSE2 sequence but not to factor-binding sequences from several 
other genes (124). Within the aP2 FSE2 sequence, Fos complexes bind DNA 
containing the sequence TGACTCA, previously identified as the consensus 
sequence for the binding of mammalian transcription factor AP-1 and yeast 
transcription factor GCN4 (125). Consistent with the suggested regulatory role 
for FSE2 is the observation that Fos complex exerts a negative regulatory effect 
on aP2 gene expression in undifferentiated 3T3-F442A cells. Another study 
showed that at least two distinct sequence elements in the aP2 promoter 
contribute to the expression of chimeric gene in transfection assays (126). An 
AP-1 site shown to bind to Jun- and Fos-like proteins, serve as a positive 
regulator of gene expression in adipocytes only, and C/EBP binding sequences 
upstream to the AP-1 site can stimulate expression in fat cells in the intact aP2 
promoter. This indicates that sequences which bind C/EBP and the Fos-Jun 
complex play major roles in the expression of the aP2 gene during adipocyte 
differentiation (126). However, recent evidence using a series of transgenic 
mice containing 5' flanking sequences in the aP2 promoter linked to the 
bacterial gene chloramphenicol acetyltransferase demonstrated that the 
proximal-promoter binding site for AP-1 and C/EBP were neither sufficient nor 
necessary to give adipose-tissue expression in vivo. Rather, an upstream 
adipose specific enhancer was required and sufficient for the expression of the 
chimeric gene in vivo (127). 
Also identified are sequences with homology to the triiodothyronine (T3) 
receptor binding site that are present in multiple copies in the regulatory region 
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of adipsin, aP2, and GPDH. This is in agreement with the observation that T3 
stimulates the differentiation in preadipocyte cell lines and in primary cultures 
of stromal vascular cells. In addition, GRE core sequence was identified in the 
5' flanking region of the aP2 gene which is probably responsible for the 
induction of the aP2 gene by glucocorticoids (75,84). Although several 
hormones and transcription factors have been implicated in adipose-specific 
gene expression, little is known about sequences responsible for transcriptional 
activation by each hormone. The cellular factors that interact with these 
hormones to modulate transcription also have not been identified. 
Adipocytes and Diabetes 
The major depots for whole body glucose disposal are muscle and adipose. 
Since insulin is known to facilitate glucose disposal, insufficient glucose disposal 
by these tissues can result either from absolute deficiency of insulin as in 
insulin-dependent diabetes mellitus (IDDM), or from resistance of target 
tissues to insulin as in non-insulin-dependent diabetes mellitus (NIDDM). 
Intensive studies were carried out to characterize mechanisms for cell resistance 
to insulin. The action of insulin involves many gene products. Target-cell 
resistance could therefore be due to defects affecting any protein between the 
receptor and the final insulin-regulated proteins (128). Candidate proteins 
include the insulin receptor, members of the family of glucose transporter 
proteins, several enzymes involved in glucose metabolism such as hexokinase, 
and substrates for insulin-receptor kinase or signaling intermediates (129). In 
addition, many circulating factors and physiologic states adversely affect the 
sensitivity of target tissues to insulin. Insulin resistance for instance, is 
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ubiquitous in obese people and in lean or obese patients with non-insulin-
dependent diabetes (NIDDM) (129). Investigation of target-tissue defects in 
these states indicated a complex etiology ( 4, 130) variously involving decreases 
in the number of insulin receptors( 131) or impaired insulin receptor 
autophosphorylation and tyrosine kinase activity (132), altered expression of 
insulin receptor types that are generated by alternative splicing of a primary 
gene transcript (133), impairment of insulin-stimulated glucose transport, and 
decreases in the number of GLUT4 glucose transporters as well as impairment 
of their functional activity in adipocytes of NIDDM and obese subjects (134-
138). 
Oral Hypoglycemic Agents 
Early hypoglycemic agents used for the treatment of NIDDM largely 
addressed the insulin secretory defects of the disease. In vitro studies have 
shown that first generation-sulfonylureas exert a direct and immediate 
stimulatory effect on insulin secretion from islet B cells by increasing sensitivity 
of islet B cells to the insulin-releasing effect of glucose (5). Sulfonylureas 
interact in a specific and saturable manner with a single type of binding site on 
the cell plasma membrane (5). The more complex substitutions of second-
generation sulfonylureas may be responsible for improved anchorage at the 
binding site, thus conferring greater insulin-releasing potency. In addition, 
sulfonylureas exert extrapancreatic glucose lowering effects mainly directed 
towards correcting the defects of glucose metabolism in liver, muscle and fat of 
NIDDM patients. However, sulfonylureas alone are ineffective in the control of 
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hyperglycemia if insulin is absent, but they increase the hypoglycemic effect of 
exogenous insulin (139-142). 
A novel class of hypoglycemic agents that are effective in animal models of 
NIDDM has recently emerged. Thiazolidinediones including pioglitazone, 
ciglitazone, and englitazone, were all shown to lower plasma glucose levels 
presumably by enhancing both sensitivity and responsiveness of target tissues to 
insulin. Epididymal fat pads removed from obi ob mice treated with ciglitazone 
were shown to exhibit increased response to insulin in terms of insulin-
stimulated glucose oxidation and lipogenesis (143). Such treatment did not 
change insulin binding, thus suggesting that these agents act to amplify cellular 
responses to insulin at post-receptor level(s). In agreement with this concept 
are observations that pioglitazone corrected deficits in glucose transport and 
GLUT4 mRNA and protein abundance in fat and, to a lesser extent, muscle 
cells of insulin-resistant animals, and that such actions were dependent on the 
presence of circulating insulin (6). Pioglitazone was also shown to increase 
insulin-stimulated autophosphorylation and kinase activity of the insulin 
receptor in muscle cells (144), further supporting the concept that pioglitazone 
acts to amplify post-binding steps in the insulin-response cascade. 
Proposed studies 
Our laboratory has been interested in investigating the mechanism(s) for 
insulin resistance in non-insulin-dependent diabetes mellitus, ie. how the 
function of muscle and adipose is altered in insulin resistance and what 
molecular mechanisms underlie such changes. We are also interested in 
probing the action of agents that have the potential of reversing this resistance. 
One such agent, pioglitazone, is a compound that has been identified 
empirically for its ability to lower elevated plasma glucose levels in animal 
models of NIDDM (145). 
Hypothesis 
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I propose to test the hypothesis that the antidiabetic agent pioglitazone acts 
to enhance cellular glucose utilization by promoting differentiation of 
preadipocytes to adipocytes, thus inducing expression of genes encoding glucose 
transporters and other adipocyte-specific proteins. 
In this differentiated state, adipocyte cells are known to be fully active in 
glucose uptake, storage, and metabolism. 
Specific Aims 
To conduct an in vivo animal study of such kind would be complex due to the 
simultaneous presence of multiple hormonal factors known to affect adipocyte 
differentiation. There is also difficulty in obtaining pure populations of 
precursor cells that undergo differentiation under controlled conditions. For 
these reasons, the in vitro cell culture model, the 3T3-F442A 
preadipocyte/ adipocyte cell line will be used. Since our prior in vivo studies 
showed that pioglitazone-enhanced glucose transport activity required the 
presence of insulin (6), subsequent studies will be carried out in the presence or 
absence of insulin. 
AIM 1 
To determine the basis of pioglitazone-mediated acceleration of 3T3 
differentiation from fibroblast to adipocytes by examining markers of the 
adipogenic pathway and the expression of adipocyte-specific genes. 
Experimental Design 
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1- Examine effects of pioglitazone and/ or insulin treatments on cell morphology 
and triglyceride accumulation. 
2- Examine effects of pioglitazone and/ or insulin treatments during 
differentiation on glucose transport activity and glucose transporter gene 
expression (GLUTl and GLUT4) at mRNA and protein levels. 
3- Assess effects of pioglitazone and/ or insulin treatments on differentiation-
related gene expression of adipocyte-specific genes ( aP2, adipsin, insulin 
receptor) at the mRNA level. 
4- Since insulin has been reported to down-regulate some messages after 
differentiation, mRNA abundance in some cases will be assessed after the 
removal of the differentiation inducer (insulin or pioglitazone) to rule out such 
effect. 
AIM2 
To probe mechanisms underlying differentiation-dependent changes in 
mRNA levels of glucose transporters and other highly regulated genes. 
Experimental Design 
1- Assess whether changes of mRNA levels are due to changes in the 
transcription rate. 
2- If changes in mRNA abundance are not fully explained by changes in 
transcription rate, I will examine the stability of mRNA for selected genes. 
Project Significance 
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This study of adipocyte cell differentiation induced by a novel hypoglycemic 
agent will deal with several important areas. First, it will provide useful insight 
into the regulatory mechanisms involved in the adipocyte differentiation and 
development, and information on the molecular basis for the development of 
responsiveness to certain hormones such as insulin. Second, adipocytes are 
known to play an important role both in normal physiology as a major site for 
energy storage and release, and in certain pathological states such obesities and 
obesity-linked diabetes. Therefore, studying the adipocyte gene expression is of 
great interest because it might provide clues on how disordered gene expression 
in such disease states would adversely affect the adipocyte function. In addition, 
this study will expand our understanding of how the hypoglycemic agent 
pioglitazone acts in vivo to enhance insulin sensitivity of target tissues thus 
correcting elevated blood glucose levels in diabetes. Finally, this combined use 
of cell culture and pioglitazone treatment should prove to be a useful model 
system with which to study the molecular mechanisms underlying insulin action 
on glucose transport. 
CHAPTER III 
MATERIALS AND MEIHODS 
3T3-F442A cells (39) were kindly provided by Dr. J. Schwartz (University of 
Michigan, Ann Arbor, MI) and pioglitazone was provided by the Upjohn Co. 
(Kalamazoo, MI). All tissue culture media and reagents were obtained from 
Sigma Co. (St. Louis, MO). Culture plates were purchased from Coming glass 
works (Coming, NY). Guanidine isothiocynate and formamide were purchased 
from International Biotechnologies, Inc. (New Haven, CT). Nytran nylon 
membranes were purchased from Schleicher and Schuell (Keene,NH), and 
Riboprobe preparation kits were obtained from Promega Corp. (Madison, WI). 
Cytidine 5' -[a-32p] triphosphate ( > 800Ci/ mmol), U ridine 5' -[ a-32P] 
triphosphate (800Ci/mmol), and D-[U-14C] Glucose (>230 mCi/mmol) were 
purchased from Amersham Corp. (Arlington Heights, IL). Immobilon PVDF 
membranes were obtained from Millipore Corp. (Bedford, MA). Immunoblot 
assay kit and the alkaline phosphatase-conjugated secondary antibody (GAR-
AP) were purchased from Bio-Rad (Richmond, CA). Nonident P40 was 
purchased from Boehringer Mannheim (W. Germany). All other chemicals 
were obtained from Sigma Chemical Co. (St.Louis, MO). 
Cell Culture and Differentiation 
Cells were routinely grown in Dulbecco's Modified Eagle's medium 
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(DMEM; 4.5 g/liter glucose) in the presence of 10% (vol/vol) calf serum. All 
formulations of DMEM contained glutamine (2 mM), penicillin (50 U/ml), 
streptomycin (50 µg/ml), and fungizone (0.25 µg/ml). The cells were 
inoculated onto 100-mm culture dishes at a density of 500/ cm2, or 35-mm 6-
well plates at a density of 1500/ cm2, then were grown to confluence and 
maintained at 37°C in a humidified 10% C02190% air atmosphere. Medium 
was changed every 2-3 days. To induce differentiation to adipocytes, confluent 
fibroblast cultures were switched to differentiation medium, DMEM containing 
10% (vol/vol) fetal calf serum and supplemented with insulin (1 µg/ml), 
pioglitazone (1 µM) unless otherwise indicated. Cell differentiation was 
assessed judging cell morphology under phase contrast microscopy; cells were 
considered to be adipocytes if numerous lipid droplets were observed in the 
cytoplasm. The cell line was used during 10th to 20th passage after clone 
isolation. To maintain a stock of 3T3-F442A fibroblasts at an early passage, 
cells were frozen in 15% (vol/vol) Dimethyl Sulfoxide (DMSO)/ culture 
medium and stored in liquid nitrogen. 
Measuzement d T n"glyceride Accumulation 
Triglyceride accumulation was measured by an organic extraction method 
adapted from J. Schwartz (146). Briefly, monolayers of 3T3-F442A cells on 100-
mm dishes were washed once with sterile phosphate buffered saline (PBS, 2.68 
mM KCl, 8.1 mM Na2HP04, 1.5 mM KH2P04, 136.9 mM NaCl) and released 
from the plate with 3 ml of 0.05% trypsin-EDTA (Gibco Co., Grand Island, 
NY) in sterile PBS. An aliquot of cells was delivered to a hemocytometer for 
cell counting and another measured aliquot (0.3 ml) was delivered into 5 ml 
Dole's reagent (isopropyl alcohol: heptane: 1NH2S04;40: 10: 1), then 3 ml 
heptane and 2 ml water were added to convert into a 2-phase system. After 
vigorous mixing, the phases were allowed to separate and the volume of the 
upper heptane phase was measured. A volume of the upper heptane phase (3 
ml) was delivered into a tared glass scintillation vial, dried, and the vial was 
weighed. The difference in weight indicates triglyceride amount. 
Cell counting 
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Cell monolayers were washed with PBS and released from plate with 3 ml ( 1 
ml for 35-mm plates) 0.05% trypsin-EDTA. A drop of cell suspension was 
placed in the upper and lower chambers of a hemocytometer, and cells in a total 
of 10 (1mm2x0.1 mm) squares were counted. This gives the number of cells in 
O.lmm3. 
Cell/ cm3 = cells counted x 10,000/ 10 (number of squares counted). 
Calculation of triglyceride accumulation per cell 
mg triglyceride per ml cell suspension: 
[mg triglyceride x total vol. heptane phase/3.0 (ml heptane used)] x [1/0.3 (ml 
of cell suspension used)] 
This number divided by the number of cells in a ml yields mg triglyceride per 
cell. 
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Measwement d 2-deoxy [14CJ Glucose Uptake 
Cell monolayers on 35-mm, 6-well plates (Corning brand) were rinsed once 
with PBS, and incubated in assay medium [DMEM, no-glucose, 5 mM sodium 
bicarbonate, 25 mM N-2-hydroxyethylpiperazine-N' -2-ethanesulfonic acid 
(HEPES), pH 7.4, 0.1% bovine serum albumin BSA; BIOLOGOS INC. 
Naperville, IL] 15 min at 22°c. 0.5 µCi of D-(u-14c] glucose in assay medium 
was added to each well and further incubated 15 min at 22°c. The cells were 
rinsed three times with PBS + 10 mM glucose, and solubilized by incubation 
with 0.9 ml of 0.5 N NaOH 30-40 min at 37°C, and transferred to vials. The 
mixture was neutralized by addition of 105 µl glacial acetic acid, and 
radioactivity was counted using 10 ml Beckman Ready-Solv CP (147). 
Cell countin~ and calculations 
Cells corresponding to each treatment condition were released from 35-mm, 
6-well plates with 1 ml of 0.05% trypsin-EDTA and were counted using 
hemocytometer as described under triglyceride accumulation. Cell-associated 
radioactivity measured by scintillation counting as Disintegrations per minute 
(DPM) was divided by the number of cells for each treatment condition to yield 
DPM per cell. 
N01them Blot Analysis d RNA 
Total RN A was extracted from cell monolayers by the guanidinium 
isothiocyanate extraction method adapted from Chomczynski and Sacchi (148). 
Briefly, cell monolayers were rinsed with sterile PBS and scraped into guanidine 
thiocyanate solution (4 M guanidine thiocyanate, 25 mM sodium citrate, 0.5% 
33 
Sarkosyl and 0.1 M 2-mercaptoethanol; GTS), and extracted with 
phenol/ chloroform in the presence of high salt concentration. The two layers 
were separated by centrifugation at 7,800 xgand RNA in the aqueous layer was 
precipitated with an equal volume of isopropanol at -70°C. RNA was further 
resuspended in GTS and reprecipitated, and the final RNA pellet was 
resuspended in DEPC (Diethyl pyrocarbonate)-treated H20 and stored at -
10°c. RNA yield was calculated using an O.D. 260 reading in 
spectrophotometer and assuming each 1 O.D. unit = 40 µg/ml RNA. 
Electrophoretic size-fractionation of RN A ( 10 µg/lane) through 1 % agarose 
gels and transfer to nylon membranes were performed according to the 
technique of Fourney et al (149). RNA was cross-linked to the membrane using 
a UV Stratalinker (Stratagene, La Jolla, CA) and hybridized to antisense RNA 
Riboprobes prepared according to kit protocols (Promega Corp.). 
High stringency hybridizations were performed at 65°C in a solution of 10% 
dextran sulfate, 50% formamide, 5 x SSPE (1 x SSPE = 180 mM NaCl, 10 mM 
NaP04, and 1 mM EDTA, pH 7.4), 5 x Denhardt's solution (100 x = 2% Ficoll, 
2% BSA, and 2% polyvinylpyrrolidone ), 0.1 % sodium dodecyl sulfate (SDS), 
and denatured sheared salmon sperm DNA (100 µg/ml). Dextran sulfate was 
omitted in some cases from hybridization solution to reduce background. The 
membranes were washed at 70°C twice in 2 x SSC (1 x = 150 mM NaCl and 15 
mM sodium citrate, pH 7.0) with 0.1 % SDS and twice in 0.1 x SSC with 0.1 % 
SDS. Membranes were exposed to Kodak XAR-5 film (Eastman Kodak, 
Rochester, NY) or to Amersham Hyperfilm-MP (manufactured for Amersham 
by CEA AB, Sweden) at -70°C with an intensifying screen (2-16 hr). 
Autoradiographic bands were quantitated by two dimensional densitometry on 
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a Bio-Rad 620 Scanner (Richmond, CA) or on an AMBIS image acquisition 
analysis system (San Diego, CA). Hybridizations were performed under 
conditions where autoradiographic detection was in the linear response range. 
To correct for unequal RNA loading, Northern blots were photographed with 
Polaroid type55 positive/ negative black and white film, and the fluoresence of 
the ethedium bromide-intercaleted 28S rRNA band on negative films was 
quantitated by two dimensional densitometry. The system was validated by 
demonstrating that the signal was linear at least over the range of 1-12.5 µ.g 
RNA/lane (150,151). 
Description of plasmids 
Riboprobes for GLUTl were prepared using the entire coding region of rat 
brain glucose transporter from pSPGT-1 (152) obtained from Dr. Graeme Bell 
(Chicago, IL). The insert was excised using Bgl II and subcloned into the Barn 
HI site of pGEM-4Z. The construct was linearized with Eco RI, and TI RNA 
polymerase was used for preparation of Riboprobes. 
Riboprobes for GLUT4 were similarly prepared using pSM 1D2 obtained 
from Dr. Morris Birnbaum (Boston, MA). The construct contains a 1.5-kilobase 
(kb) 5' fragment of cDNA encoding the rat GLUT4 protein (153). This 
construct was linearized with EcoRI, and TI RNA polymerase was used for 
transcription. 
Riboprobes for adipsin were prepared using pGEM-4Z containing a mouse-
940bp insert (pAD-20) from Pst I site of pBR322 (85) obtained from Dr. Bruce 
Spiegelman (Boston, MA) and subcloned in our laboratory. The construct was 
linearized with Eco RI and TI RNA polymerase was use for transcription. 
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Similarly, Riboprobes for aP2 were prepared using a mouse-390bp insert 
called pAd-5 (85) obtained from Dr. Bruce Spiegelman and subcloned in our 
laboratory from pBR322 into the Pst I site of pGEM-4Z. The construct was 
linearized with Hind III, and SP6 RNA polymerase was used for preparation of 
Riboprobes. 
For the insulin receptor (IR), a 775bp insert for the mouse insulin receptor 
(original clone provided by Dr. G. Bell and has not been formally described in 
the literature) was subcloned in our laboratory from pUC into the EcoRI site of 
pGEM-3Z. It was linearized with Hind III, and 17 RNA polymerase was used 
for preparation of Riboprobes. 
Plasmid DNA preparation 
Plasmid DNA was prepared using Qiagen plasmid preparation kit (Qiagen 
Inc. Chatworth, CA). Cultures were inoculated from frozen (-70°C) stocks of 
Ecoliusing 10 µl per 50 ml of 2.5% LB Broth culture medium, and incubated 
overnight in an environmental shaker at 200-250 rpm. Cells were harvested by 
centrifugation when the O.D.600 reached 1-1.5, and plasmids were isolated 
following the kit protocol. This procedure yielded 100 µg (midi-prep kit) to 500 
µg (maxi-prep kit) DNA. 
Western Immunoblot Analysis 
Total particulate membrane proteins were prepared as previously described 
(61). Briefly, cells were washed with PBS and scraped into homogenization 
buffer (20 mM Tris, 255 mM Sucrose, 1 mm ethylenediaminetetraacetic acid 
EDTA, 1 mm phenylmethyl sulfonyl fluoride PMSF, 10 units/ml Trasylol) and 
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were homogenized with ten strokes of Tekmar tissumizer (Tekmar Inc, 
Cincinnati, OH). Total membranes were prepared by centrifugation of the 
homogenate at 200,000 xg4°C 75 min. Protein concentrations were determined 
by the Bradford assay (154) using Bio-Rad/Bradford Protein Assay Kit and 
bovine serum albumin as a standard. Initial Western blot experiments revealed 
diffuse bands of GLUTl and GLUT4 proteins, possibly due to heterogeneous 
glycosylation of the transporter proteins. Therefore, protein samples were 
routinely treated with peptide N-glycosidase F (1 unit per 100 µg protein; 
Boehringer Mannheim) in a buffer containing 20 mM sodium phosphate, pH 
7.5, 10 mM EDTA, 1.7% Triton x-100, 1 mm PMSF for 48-72 hr at 37°c (109) 
to remove sugar residues, and then mixed with 1/ 4 vol of 4 x electrophoretic 
sample buffer (200 mM Tris-HCl, pH 6.8, 400 mM dithiothreitol, 8% SDS, 40% 
glycerol, 0.4% bromophenol blue) and stored at -20°C. Samples were thawed 
and loaded in parallel onto two discontinuous 12% polyacrylamide gels, and 
size-fractionated using a Mini Protean II Dual Slab Cell (Bio-Rad) according to 
the method of Laemmeli (155). The amount of protein loaded (10 µg/lane for 
GLUTl and 60 µg/lane for GLUT4) was empirically determined to be within 
the linear response range of the detection system used. Separated proteins 
from both gels were electrophoretically transferred to Immobilon PVDF 
membranes (Millipore Corp., Bedford MA) using a Mini Trans-Blot 
Electrophoretic Transfer Cell (Bio-Rad). One membrane was stained with 
Coomassie R-250 (0.1% Coomassie R-250, 40% methanol, 10% acetic acid) for 
total protein. The second membrane was used for the colorimetric detection of 
GLUTl or GLUT4 using a double antibody system and the Immuno-Blot Assay 
Kit (Bio-Rad). Manufacturer's instruction were followed, except 5% BSA was 
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used for membrane blocking. The primary antibody (RaIRGT, against GLUT4 
and RaGLUTRANS against GLUTl, East Acres Biologicals, Southbridge, MA) 
were diluted to 1:2000 and 1:3000 respectively and the alkaline phosphatase-
conjugated second antibody (GAR-AP, Bio-Rad) was diluted 1:3000 before use. 
Resulting signals were quantitated with the reflective mode of a model 620 
Video Densitometer (Bio-Rad). Sample loading corrections were made based 
on densitometry data from the Coomassie-stained membrane. 
Run-on Transcription Activity 
Nuclei were isolated from 3T3-F442A cells by a method adapted from 
Konieczny et al (156). Cell monolayers were washed twice with resuspension 
buffer RSB (10 mM Tris, pH 7.5, 10 mM NaCl, 3 mM MgCl2); scraped from 
plates in RSB + buffer (10 mM Tris, pH 7.5, 10 mM NaCl, 3 mM MgCl2, 0.5% 
N onident P40, 2.75 mM DTT), and disrupted by 10 strokes in a Dounce glass 
homogenizer. The nuclei were concentrated by centrifugation at 1000 x g and 
suspended in nuclei suspension buffer NSB (50 mM HEPES, pH 8.0, 5 mM 
MgCl2, 0.1 mM EDTA, pH 8.0, 2 mM DTT, 40% glycerol) stored at -70°C. 
Nuclear transcription assays were adapted from Sasaki et al (157) with some 
modifications. Briefly, after thawing on ice, equal amounts of nuclei (0.5-1 mg 
DNA) - assessed by fluorometric quantitation of DNA (158)- were used in 
assays carried out at 26°C for 20 min in a solution of 75 mM Hepes, pH 8.0, 100 
mM KCl, 0.1 mM EDTA, 0.1 mM PMSF, 0.5 mM CTP, 0.5 mM ATP, 0.5 mM 
GTP, 0.25 U/ml RNasin, 1 µCi/ µl aP32_UTP -800 Ci/mM) in a total reaction 
vol of 140 µl. The assays were terminated by incubation with 2 x stopping buffer 
(40 mM Tris, pH 7.5, 20 mM CaCl2, 200 µg/ml proteinase K, 250 µg/ml tRNA, 
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5 U/ml RNase-free DNase) for 20 min at 37°C. Nuclei were digested with 
EDTA/SDS (100 mM EDTA, pH 8.0, 8% SDS) for 10 min at 37°C and RNA 
was isolated by chloroform/phenol extraction (1:1), and precipitation with 7.5 
M ammonium acetate-100% ethanol. RNA transcripts were resuspended in 1 x 
stopping buffer (without tRNA) and incubated for 20 min at 37°C, followed by 
another EDTA/SDS digestion, phenol/ chloroform extraction and precipitation 
as above. The transcripts were suspended in T.IE suspension buffer (0.1 mM 
EDTA, pH 8.0, 10 mM Tris, pH 7.5) and reprecipitated. RNA transcripts were 
resuspended in 200 µl hybridization solution (50% formamide, 5 x SSPE, 5 x 
Denhardt's solution, 0.1 % SDS, 200 µgl ml denatured sheared salmon sperm 
DNA solution), the amount of RNA-associated 32P-radioactivity determined by 
liquid scintillation counting. Samples were adjusted to contain equal amounts 
of radioactivity using hybridization solution (1-2 x 107 cpm). Hybridizations 
were carried out in a total volume of 500 µ.l at 65°C for 18-24 hr using nylon 
membranes to which 1 µ.g of each cRNA was applied using a dot-blot apparatus 
(Mini-fold, Schleicher and Schuell, Keene, NH) and attached by UV cross-
linking. 1 µg was empirically found to be appropriate for signal detection. Each 
cRNA was prepared from its vector plasmid as described for Northern Blotting 
using RNA Riboprobe Kit according to kit protocol (Promega Corp.), and 
confirmation of full length transcripts was made by electrophoresis with 
molecular markers on 1 % agarose gel. cRNA Riboprobes for the plasmid 
vector control (pGEM-4Z) and appropriate genes were denatured in a solution 
containing 50% formamide, 16.2% formaldehyde for 15 min at 65°C and 
applied to the membrane in 10 x SSC buffer. Membranes were first 
prehybridized for 2 hr at 65°C in hybridization solution. After hybridization, 
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filters were washed at 70°c twice in 2 x SSC with 0.1 % SOS and twice with 0.1 x 
SSC with 0.1 % SOS. Membranes were then exposed to Kodak XAR-5 films at -
10°c for 2-4 days. Filters were then cut and 32P-labeled radioactivity 
hybridized to each cRNA Riboprobe was released from filters with 0.04 N 
Na OH and neutralized with 0.1 N acetic acid. Five ml of Beckman Ready-Solv 
CP scintillation fluid were added and radioactivity was quantitated by 
scintillation counting. 
DNA quantitation by fluorescence 
To determine the amount of nuclei needed for each transcription reaction, 
the amount of DNA was measured according to the method of Labarca and 
Paigen (158). Briefly, an aliquot of nuclei was delivered into phosphate-
buffered saline with EDTA (PBSE = 0.05 M Na2HP04, 2 M NaCl, 2 mM 
EDTA, pH 7.4) and sonicated for 10 seconds. The compound Hoechst 33258, 
(2-[2-( 4-hydroxy phenyl)-6-benzimidazolyl ]-6-( 1-methyl-piperazyl)-
benzimidazol.3H Cl) (Sigma Co. St.Louis, MO), was added to each sample and 
the fluorescence enhancement was measured in fluorometer with excitation set 
at 356 nm and emission set at 458 nm. Calf thymus DNA was used to generate 
a standard curve. 
Measwement d mRNA Stability 
Confluent monolayers of 3T3-F442A cells were differentiated with insulin, 
pioglitazone or both agents as described under cell culture and differentiation. 
On day 7 of differentiation, mRNA synthesis was inhibited by addition to the 
medium of actinomycin D-mannitol (Sigma Co. St.Louis, MO) to a final 
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concentration of 5 µglml. Total RNA was extracted from separate monolayer 
cultures at 0, 1, 2, 4, 6, and 24 hr after the addition of transcription inhibitor. 
Messenger RNA transcript abundance was determined by Northern blot 
analysis and hybridization and densitometry of resultant autoradiographic bands 
as described above. 
Calculations 
Data were expressed as percent of mRNA remaining after actinomycin D 
treatment relative to their levels before the treatment (time 0). The half life of 
each message was calculated using the Enzfitter program (Elsevier Biosoft, 
Elsevier Science Publishers, Amesterdam). mRNA levels were fitted to a 
single exponential decay curve according to the equation y = Exp (-k.t) by non 
linear least square regression analysis. In this equation, y, is the concentration 
at time 't', and k is the first order rate constant of the exponential decay plot. 
The half-life of mRNA was then calculated by dividing ln2 with k. 
Statistical Analysis 
Statistical analysis was performed using SAS version 6 (SAS institute, Inc., 
Cary, NC). All hypothesis tests were two-sided and were considered significant 
if p-value was less than or equal to .05 
Dose-response experiments were analyzed using one-factor analysis of 
variance (ANOVA). In one set of analyses, the factor was dose of insulin, and 
in the second set of analyses, the factor was dose of pioglitazone. If there was a 
significant dose response, then Tukey's pairwise comparison procedure was 
used to locate the differences among dose levels. 
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Time-course experiments were analyzed using a three-factor analysis of 
variance (ANOVA) with interactions procedure. The factors used were day of 
the experiment, insulin or control, pioglitazone or control. Beginning with the 
higher order interaction terms, successive models were run deleting one non-
significant factor or interaction at a time until the final model only contained 
terms which were significant at p ..::;.0.05. 
Protein experiments and time-course experiments, in some cases, were 
analyzed using a two-factor analysis of variance with interaction procedure. 
CHAPTER IV 
RESULTS 
Hfects d insulin and pioglitawne on 3T3-F442A preadipocyte differentiation 
Treatment of confluent 3T3-F442A cells with insulin (1 µg/ml), pioglitazone 
(1 µM), or both agents in the presence of 10% fetal calf serum resulted in 
conversion of cells into lipid-accumulating adipocytes as assessed by phase 
contrast microscopy (Table I, Figure 1). While only limited numbers of cells 
differentiated into adipocytes by either treatment alone, both agents had 
approximately additive effects shown most clearly on day 3 (I, 8 .± 3; P, 15 .± O; 
I+ P, 30 + 5) and day 5 (I, 42 .± 8; P, 45 .± 4; I+ P, 84 .± 5) and reaching 
maximal levels on day 7 (I+ P, 95 .± 0) of differentiation. These morphological 
changes were accompanied by time-dependent changes in cellular triglyceride 
content (Figure 2), assessed by organic extraction of triglyceride. This effect 
was measurable on days 3, 5, and 7. There were marked changes on day 7 of 
differentiation (C, 0.39 .± 0.05; I, 0.599 .± 0.07; P, 1.34 .± 0.19; I+ P, 2.2 .± 0.27). 
These results indicate that both insulin and pioglitazone act as accelerators of 
adipocyte differentiation and that their effects are additive or synergistic. 
Hfects d insulin and pioglitawne on glucose transpoit activity and glucose 
transpoiter ~ne expression 
To determine whether the observed cell differentiation was accompanied 
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Table I. Pioglitazone and insulin-dependent differentiation of 3T3-F442A 
expressed as% differentiated cells. 
Day cs INS PIO INS+PIO 
0 0 
1 0 2 2 3 
3 2 8 15 30 
5 2 42 45 84 
7 2 60 80 95 
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Cells were plated, grown to confluence and maintained in Dulbecco's 
modified Eagle's medium (DMEM) supplemented with 10% calf serum. To 
induce differentiation, cells were switched to DMEM medium supplemented 
with 10% fetal calf serum, insulin (INS), pioglitazone (PIO) or both (I+ P) as 
described under materials and methods. Untreated age-matched fibroblasts 
maintained in growth medium with only calf serum (CS) were used as control. 
Cell differentiation was assessed by phase contrast microscopy. Data represent 
mean values for n = 2-6 determinations. One-way analysis of variance 
(ANOV A) on day 7 for CS vs INS, CS vs PIO, CS vs INS+ PIO, p < 0.0001. 
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B. Adipocytes 
Figure 1. Phase contrast microscopy showing the change in morphology upon 
differentiation from preadipocytes (A) to adipocytes (B) induced by treatment 
with a combination of insulin and pioglitazone. Magnification x300. 
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Figure 2. Time-course showing increasing abundance of triglyceride during 
differentiation of 3T3-F442A fibroblasts into adipocytes. 3T3-F442A cells were 
plated, grown to confluence and differentiated with INS (1 µg/ml), PIO (1 µM), 
or both (INS+ PIO) as described under materials and methods. At indicated 
time points, triglycerides were extracted from cells with Dole's reagent and the 
organic layer was dried. Triglyceride accumulation was determined by weighing 
the dried residue. Untreated age-matched fibroblasts maintained in growth 
medium (CS) were used as control. 
Each data point represents mean ± S.E.M for n = 9 determinations. A three 
factor analysis of variance (ANOV A; insulin, pioglitazone, time) with 
interactions showed significant time-dependent effects on triglyceride 
abundance by INS (p = 0.017), PIO (p <0.0001), INS+ PIO (p = 0.02). 
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with changes in cellular metabolic activities, we examined the transport level of 
2-deoxy [ 14c] glucose into cells differentiated with insulin and/ or pioglitazone 
as compared to control undifferentiated cells. Differentiation of 3T3-F442A 
cells with insulin, pioglitazone, or both agents, resulted in enhanced basal 2-
deoxy glucose transport in a time-dependent manner (Figure 3). While either 
insulin or pioglitazone alone showed respectively 22- and 29-fold enhancement 
above control of glucose transport on day 7 of differentiation, both agents acted 
synergistically to increase glucose transport activity on each of the days 
examined, reaching maximal levels of 96-fold on day 5 and seemingly started to 
decline to lower levels ( 46-fold) on day 7 of differentiation. Age-matched 
undifferentiated cells kept in growth medium showed no increase glucose 
transport during the same period of time, and even showed a 40% decline in 
their rate of glucose transport by day 7, possibly an indication of the cells 
becoming more quiescent. 
To assess whether such enhanced glucose transport activity could be 
explained by changes in adipocyte-glucose transporter expression, we analyzed 
the levels of GLUTl and GLUT4 mRNA and protein abundance. GLUTl 
mRNA abundance increased in a dose-dependent manner reaching maximal 
levels of 2.5-fold and 2-fold after 7 days of treatment with 10 µgl ml insulin 
(Figure 4A) and 10 µM pioglitazone (Figure SA), respectively, as compared to 
undifferentiated control cells (day 0). Age-matched undifferentiated cells kept 
in growth medium showed < 10% increase in GLUTl mRNA abundance at the 
same time. In contrast to this moderate elevation of GLUTl mRNA, GLUT4 
mRNA abundance was dramatically increased in a dose-dependent manner as 
much as 20-fold above its levels in undifferentiated cells by either insulin 
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(Figure 4B) or pioglitazone (Figure SB). Age-matched cells kept in growth 
medium showed <2.5-fold increase in GLUT4 mRNA abundance. 
Furthermore, GLUT4 mRNA abundance was significantly increased by the 
lowest tested dose of each of insulin and pioglitazone, with maximal effects at S 
µglml insulin (Figure 4B) and 1 µM pioglitazone (Figure SB). 
In addition, both mRNA transcripts analyzed by Northern blotting, increased 
in a time-dependent manner during differentiation. While either insulin (1 
µg/ml) or pioglitazone (1 µM) treatment increased GLUTl mRNA abundance 
by 2.3- and 1.S-fold, respectively, above undifferentiated cells (day 0), insulin 
and pioglitazone together acted synergistically to increase this message by 
almost 6-fold by day 7 (Figure 6). GLUTl mRNA levels did not change during 
the same period in undifferentiated age-matched cells kept in growth medium. 
In contrast to the observed synergism on GLUTl mRNA, GLUT4 mRNA 
abundance increased to similar levels above undifferentiated cells (day 0), 3.8-, 
4.6, and S.2-fold by insulin, pioglitazone, or both, respectively (Figure 7). 
These changes in GLUTl and GLUT4 mRNA levels were accompanied by 
changes in their respective protein products as assessed by Western blotting. 
While either insulin or pioglitazone treatment increased GLUTl protein levels 
on day 7 of differentiation by 2.3-and 3.5-fold, respectively, both agents acted 
synergistically to increase GLUTl protein levels by almost 10-fold (Figure 8) 
above those in their age-matched undifferentiated cells. In contrast to the 
observed synergistic effect on GLUTl protein, GLUT4 protein levels increased 
by 2.2-, 6.6-, and 4-fold by insulin, pioglitazone, or both, respectively (Figure 9). 
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Figure 3. Time-course showing increasing glucose transport activity during 
differentiation. Confluent 3T3-F442A cells on 35 mm, 6-well plates were 
induced to differentiate into adipocytes by insulin (INS), pioglitazone (PIO) or 
both (INS+ PIO). On indicated time points, glucose transport activity was 
determined by measuring cell-associated radioactivity following the uptake of 2-
deoxy-D-[U-14c] Glucose as described under materials and methods. 
Untreated, age-matched fibroblasts maintained in calf serum growing medium 
(CS) were used as control. Each data point represents mean.± S.E.M for n = 3 
determinations. A two way analysis of covariance (ANCOVA) showed 
significant effects on glucose uptake by INS (p = 0.0006), PIO (p < 0.0001 ), 
INS+ PIO (p <0.0001). 
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Figure 4. Insulin dose effect on GLUTl and GLUT4 mRNA abundance. 3T3-
F 442A cells were plated and grown in DMEM containing 10% calf serum. To 
induce differentiation, confluent fibroblasts were maintained in DMEM 
containing 10% fetal calf serum and supplemented with insulin at 0, 0.1, 1, 5, 10 
µglml. Total RNA was isolated from cells on day 7. Samples of total RNA (10 
µgllane) were electrophoretically size-fractionated on agarose gels, and 
Northern blots were hybridized to Riboprobes specific for the rat GLUTl 
mRNA (A), or the rat GLUT4 mRNA (B). Autoradiographic bands were 
quantitated by densitometry and normalized for loading based on the 
abundance of the 28S ribosomal RNA. Each data point represents mean± 
S.E.M for n = 6 determinations. One way ANOV A showed significant dose-
dependent effect of insulin treatment on mRNA abundance for GLUTl (p 
<0.0001) and GLUT4 (p = 0.006). 
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Figure 5. Pioglitazone dose effect on GLUTl and GLUT4 mRNA abundance. 
3T3-F442A cells were plated and grown to confluence as described under 
materials and methods. Differentiation was induced by maintaining cells in 
DMEM containing 10% fetal calf serum and supplemented with 0, 0.1, 1, 5, 10 
µM pioglitazone. Total RNA was isolated from cells on day 7, and samples of 
10 µg/lane were electrophoretically size-fractionated on agarose gels. Northern 
blots were hybridized to Riboprobes specific for the rat GLUTl mRNA (A), or 
the rat GLUT4 mRNA (B). Autoradiographic bands were quantitated by 
densitometry and normalized for correct loading base on the 28S ribosomal 
RNA abundance. Each data point represents mean ± S.E.M for n = 6 
determinations. One way ANOVA demonstrated significant dose-dependent 
effect of pioglitazone on mRNA abundance for GLUTl (p <0.0001) and 
GLUT4 (p = 0.0001) 
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Figure 6. Effect of insulin and pioglitazone treatments on GLUTl mRNA 
abundance. A, Time-course showing increasing abundance of GLUTl mRNA 
during differentiation of 3T3-F442A cells. Cells were plated, grown to 
confluence and differentiated with insulin (INS), pioglitazone (PIO), or both 
(INS+PIO) as described above. Total RNA was isolated on indicated time 
points (days 1, 3, 5, 7). 10 µg of total RNA were electrophoretically size-
fractionated on agarose gels and Northern blots were hybridized to Riboprobes 
specific for rat GLUTl mRNA. Autoradiographic bands were quantitated by 
densitometry and normalized for loading based on 28S ribosomal RNA 
abundance. Untreated age-matched fibroblasts maintained in growth medium 
(CS) were used as control. 
Data represent mean values for n = 5-6 determinations. A three factor analysis 
of variance (insulin, pioglitazone, time) with interactions showed significant 
effect on GLUTl mRNA abundance from combined treatment with insulin and 
pioglitazone (p = 0.0001). B, Representative blot showing GLUTl mRNA 
abundance in control CS cells and in cells treated with INS, PIO, INS+ PIO on 
day 7 of differentiation. 
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Figure 7. Effect of insulin and pioglitazone treatments on GLUT4 mRNA 
abundance. A, Time-course showing increasing abundance of GLUT4 mRNA 
during differentiation of 3T3-F442A cell. Cells were plated, grown to 
confluence, and differentiated by insulin (INS), pioglitazone (PIO) or both 
(INS+ PIO) as described above. On indicated time points, total RNA was 
isolated and 10 µg of it were electrophoretically size-fractionated on agarose 
gels. Northern blots were hybridized to Riboprobes specific for rat GLUT4 
mRNA. Autoradiographic bands were quantitated by densitometry and 
normalized for loading based on the 28S ribosomal RNA abundance. 
Untreated age-matched fibroblasts maintained in growth medium (CS) were 
used as control. Each data point represents mean values for n = 5-6 
determinations. A three factor analysis of variance (insulin, pioglitazone, time) 
with interactions showed significant effects on GLUT4 mRNA abundance by 
INS (p = 0.0001) or PIO (p <0.0001). B, Representative blot showing GLUT4 
mRNA abundance in control (CS) and treated (INS, PIO, INS+ PIO) cells on 
day 7 of differentiation. 
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Figure 8. Effect of insulin and pioglitazone treatments on GLUTl protein 
abundance. Confluent 3T3-F442A cells were differentiated with 1 µ.g/ml 
insulin (INS), 1 µ.M pioglitazone (PIO), or both (INS+ PIO), as described 
above. On day 7, membranes were isolated from undifferentiated (CS) or 
differentiated (INS, PIO, INS+ PIO- treated) cells, and 10 µ.g of protein were 
electrophoresed and immunoblotted for GLUTl detection using the rabbit anti-
GLUTl primary antibody as described under materials and methods. Resulting 
colorimetrically-stained bands were quantitated with densitometry and 
normalized for loading based on desitometry data from Coomassie-stained 
membranes. Data are expressed as% of control and represent mean± S.E.M 
for n = 8 determinations. Two factor analysis of variance showed significant 
effects on GLUTl protein by INS (p = 0.014), PIO (p = 0.015), and INS+ PIO 
(p <0.0001). In control cells (CS), a non-specific band of an apparent 
molecular weight of 60,000 (shown at arrow) cross reacted with secondary 
antibody. Molecular weight markers are indicated in lane M. 
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Figure 9. Effect of insulin and pioglitazone treatments on GLUT4 protein 
abundance. Cell culture, treatment conditions, protein extraction, and Western 
blot analysis were performed as described in the legend for Figure 8, except that 
60 µ.g of total protein were loaded for GLUT4 detection using the rabbit anti-
GLUT4 primary antibody. Data are expressed as% of control and represent 
mean.± S.E.M. for n = 10 determinations. Two factor analysis of variance 
showed significant effects on GLUT4 by INS (p = 0.015), PIO (p = 0.007), 
INS+ PIO (p = 0.0003). In control cells (CS), a non-specific band of an 
apparent molecular weight of 60,000 (shown at arrow) cross reacted with 
secondary antibody. Molecular weight markers are indicated in lane M. 
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Taken together, these results indicate that differentiation of 3T3-F442A cells 
with insulin and pioglitazone is accompanied by concomitant increases in 
glucose transport activity and glucose transporter gene expression on mRNA 
and protein levels. 
Hfects d insulin and pioglitamne on expression d adipocyte-spedf ic genes 
To determine whether the observed effect on glucose transporters is a 
transporter-specific or a rather general effect on differentiation-dependent gene 
expression, we examined the effect of insulin and pioglitazone during 
differentiation on the expression of other known adipocyte-specific genes on 
mRNA level. Differentiation of 3T3-F442A cells with either insulin (1 µg/ml) 
or pioglitazone (1 µM) each increased adipsin mRNA levels in a time-
dependent manner, to as much as 5- and 11-fold on day 7 of differentiation, as 
compared to undifferentiated control cells (day 0), (Figure 10). Age matched 
undifferentiated cells kept in growth medium showed <2.5-fold increase in this 
message during the same period of time. The combined insulin/ pioglitazone 
treatment significantly inhibited expression of adipsin mRNA induced by either 
treatment alone. On the other hand, aP2 mRNA abundance assessed under the 
same conditions increased dramatically in a time-dependent manner by either 
insulin, pioglitazone, or the combined treatment. These effects were seen as 
early as day 1 of differentiation and reached maximal levels of 93- and 77-fold 
on day 3 of differentiation by pioglitazone or insulin/pioglitazone respectively, 
and after that the message levels start to decline (Figure 11). In contrast, aP2 
mRNA abundance continues to increase with insulin treatment, though to much 
lesser levels, reaching only 27-fold on day 7 of differentiation. Undifferentiated 
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age-matched control cells kept in growth medium showed <3-fold increase in 
aP2 mRNA abundance during the same period. In contrast to these high levels 
of regulation on the abundance of both adipsin and aP2 mRNAs, no effect was 
observed for any of the treatments on the abundance of insulin receptor mRNA 
under same conditions even by day 7 of differentiation (Figure 12). 
Since it is known that insulin has down-regulating effect on adipsin mRNA in 
differentiated adipocyte cells (100), and it is also known that prolonged insulin 
treatment down-regulates the insulin receptor itself in many tissues (58), we 
decided to assess the abundance of these two messages after treatment and 
withdrawal of the differentiation inducer in order to sort out differentiation 
effects and down-regulation effects. For this experiment, 3T3-F442A cells were 
differentiated with insulin (1 µg/ml), pioglitazone (1 µM), or both, in the 
presence of 10% fetal calf serum, for 7 days, after which insulin and 
pioglitazone were removed from the feeding medium and cells were kept in 
medium containing only 10% fetal calf serum for another six days (day 13). 
Total RNA was extracted from cells on day 7 and day 13, and the abundance of 
adipsin and insulin receptor mRNAs was assessed on Northern blots. 
Treatment of cells with either insulin or pioglitazone resulted in 5.6- and 6-fold 
increase of adipsin mRNA while the combined treatment resulted in about 40% 
decrease in the message on day 7 of differentiation when compared to 
undifferentiated control cells - day 0 - (Figure 13). After insulin and 
pioglitazone withdrawal, there is further increase in adipsin mRNA of about 6-
and 5.5-fold on day 13 above corresponding levels on day 7. Furthermore, such 
withdrawal from cells differentiated with the combined insulin/ pioglitazone 
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Figure 10. Effect of insulin and pioglitazone treatments on adipsin mRNA 
abundance. A, Time-course showing increasing adipsin mRNA abundance 
during differentiation 3T3-F442A cells induced by treatment with either insulin 
(INS) or pioglitazone (PIO) alone and inhibitory effect by the combined 
treatment (INS+ PIO). Cells were plated, grown to confluence and 
differentiated with INS, PIO, or both (INS+ PIO) as described under materials 
and methods. Total RNA was isolated on indicated time points, and 10 µg 
samples were electrophoretically size-fractionated on agarose gels. Northern 
blots were hybridized to Riboprobes specific for the mouse adipsin mRNA. 
Autoradiographic bands were quantitated by densitometry and normalized for 
loading based on the abundance of the 28S ribosomal RNA. Untreated age-
matched fibroblasts maintained in growth medium (CS) were used as control. 
Each data point represents mean values for n = 5-6 determinations. A three 
factor ANOVA (insulin, pioglitazone, time) with interactions showed significant 
time-dependent effects on adipsin mRNA abundance by INS (p <0.0001) or 
PIO (p <0.0001). The inhibitory effect of the combined treatment (I+ P) was 
also significant (p <0.0001). B, Representative blot showing adipsin mRNA 
abundance in control (CS) and treated (INS, PIO, INS+ PIO) cells on day 7 of 
differentiation. 
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Figure 11. Effect of insulin and pioglitazone treatments on aP2 mRNA 
abundance. A, Time-course showing increasing abundance of aP2 mRNA 
during differentiation of 3T3-F442A cells induced by INS, PIO, or INS+ PIO. 
Cells were plated, grown to confluence, and differentiated as described in 
materials and methods. Total RNA was isolated on indicated time points and 
10 µ.g samples were electrophoretically size-fractionated on agarose gels. 
Northern blots were hybridized to Riboprobes specific for the mouse aP2 
mRNA. Autoradiographic bands were quantitated by densitometry and 
normalized for loading based on the abundance of the 28S ribosomal RN A. 
Untreated age-matched fibroblasts maintained in growth medium (CS) were 
used as control. Each data point represents mean values for n = 5-6 
determinations. A two factor analysis of covariance (ANCOVA) showed 
significant effects on aP2 mRNA abundance by INS (p = 0.02), PIO (p 
<0.0001), INS+ PIO (p = 0.0002). B, Representative blot showing aP2 mRNA 
abundance in control (CS) and treated (INS, PIO, INS+ PIO) cells on day 7 of 
differentiation. 
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Insulin Receptor mRNA 
- 9.5 kb 
- 7.5 kb 
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Figure 12. Insulin and/ or pioglitazone treatments showed no significant effect 
on insulin receptor mRNA abundance. 3T3-F442A cells were plated, grown to 
confluence, and differentiated with INS, PIO, or INS+ PIO as described under 
materials and methods. Untreated age-matched fibroblasts (CS) were used as 
control. Total RNA was isolated on selected time points (day 1, 3, 5, 7) of 
differentiation. Samples of 10 g of total RNA were electrophoretically size-
fractionated on agarose gels and Northern blots were hybridized to Riboprobes · 
specific for the mouse insulin receptor mRNA. The blot represents typical 
results on day 7 of differentiation. 
68 
Figure 13. Enhanced adipsin mRNA abundance by insulin and pioglitazone 
withdrawal after differentiation. 3T3-F442A cells were plated and 
differentiated as described under materials and methods. On day 7 of 
differentiation, insulin and pioglitazone were removed from differentiation 
medium and cells were maintained in DMEM containing 10% fetal calf serum 
for 6 days after which total RNA was isolated and the abundance of adipsin 
mRNA was assessed using Northern blotting analysis as described earlier. A 
quantitation of autoradiographic bands corresponding to adipsin mRNA 
transcripts is shown. Each data point represents mean ± S.E.M for n = 4 
determinations. Student's test for unpaired groups showed significant effects for 
INS withdrawal (p = 0.007), PIO withdrawal (p = 0.002), and INS+ PIO 
withdrawal (p = 0.0002). 
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Figure 14. Enhanced insulin receptor mRNA abundance by insulin and 
pioglitazone withdrawal after differentiation. Cell culture, differentiation, 
treatments, and message abundance analysis as described for figure 13. A, 
Quantitation of autoradiographic bands corresponding to the 9.5 kb insulin 
receptor mRNA transcript. Each data point represents mean± S.E.M for n = 
4 determinations. Student's test for unpaired groups showed significant effects 
on the abundance of the 9.5 kb insulin receptor message by INS (p = 0.0002), 
PIO (p = 0.0007), and INS+ PIO withdrawal (p <0.0001). B, Quantitation of 
autoradiographic bands corresponding to the 7.5 kb insulin receptor mRNA. 
Each data point represents mean± S.E.M for n = 4 determinations. Student's 
test showed significant effects on the 7.5 kb insulin receptor message abundance 
for INS withdrawal (p = 0.005), PIO withdrawal (p = 0.0016), and INS+ PIO 
withdrawal (p < 0.0024 ). C, Representative blot showing enhanced expression 
of insulin receptor message of two sizes after insulin and pioglitazone 
withdrawal. 
Effect of INS/PIO Withdrawal on Insulin Receptor mRNA Abundance 
A. 
B. 
8 
2l 4 
c 
Ill 
"ti 
c 
:i 
.0 
<( 
<( 2 
z 
a: 
E 
0 ..._.......,_......_ __ _ 
cs 
4 
-~ 
c 
::l 
>- 3 
... 
~ 
-
-e 
< 
~ 2 
c 
as 
"tl 
c 
:i 
.0 
<( 
<( 
z 
a: 
E 
0 .................... ....._ ___ _ 
cs 
E3J Day 0 
- Day7 
~ Day13 
INS PIO INS+PIO 
Treatments 
C3J Day 0 
- Day7 
~ Day 13 
INS PIO INS+PIO 
Treatments 
71 
72 
c. 
Insulin Receptor mRNA 
- 9.5 kb 
- 7.5 kb 
cs Ins Pio l+P Ins Pio l+P 
Day 7 Day 13 
Figure 14. 
treatment showed 29-fold increase of adipsin mRNA levels on day 13 above 
their corresponding levels on day 7. 
The insulin receptor 9.5 kb message increased about 2.6- to 3.4-fold on day 
13 above corresponding levels on day 7 after insulin, pioglitazone, or 
insulin/pioglitazone withdrawal (Figure 14A, 14C). Similar results were 
obtained for the insulin receptor 7.5 kb message (Figure 14B, 14C). 
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Taken together, all these results indicate that both insulin and pioglitazone 
have general differentiation effect, causing 3T3-F442A cells to differentiate into 
adipocytes with concomitant increases in the expression of adipocyte specific 
genes. 
Hfect d insulin and pioglitaz.one on tmnscnption activity 
To assess whether observed changes in abundance of different mRNAs were 
due to changes in corresponding gene transcription rate, we performed the 
nuclear transcription run-on assay. 3T3-F442A cells were differentiated with 
insulin (1 µg/ml), pioglitazone (1 µM), or both, and nuclei were isolated from 
differentiated cells on day 7 and from undifferentiated control cells on day 0. 
Transcription activity was measured by allowing the incorporation of [32P]UTP 
into elongating nascent transcripts in isolated nuclei, and hybridizing the 
resultant labeled transcripts into immobilized cRNA Riboprobes of interest. As 
shown in Figure 15 and in Table II, transcription activity was below detection 
for GLUTl, GLUT4, and insulin receptor in control cells and no change could 
be detected with differentiated cells. Unexpectedly high levels of transcription 
activity were detected for adipsin and aP2 in undifferentiated control cells. 
There are detectable increases in transcription activity for aP2 and detectable 
decreases for adipsin in differentiated cells. In all cases, changes in mRNA 
abundance for all studied genes could not be explained by corresponding 
changes in transcription activity. 
Transcription Run-on Assay 
NIM 
-
llUT1 ... 
GLUT< crn• 
Ill 
cs INS PIO l+P 
Figure 15. Regulation of gene transcription activity by insulin and 
pioglitazone-induced differentiation of 3T3-F442A cells. Nuclei were isolated 
from cells differentiated with insulin (INS), pioglitazone (PIO), or both 
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(INS+ PIO) on day 7 of differentiation, and from preconfluent undifferentiated 
cells (CS). Transcription run-on assay by isolated nuclei was carried out as 
described under material and methods. Resultant labeled transcripts were 
hybridized to indicated cRNAs (1 µg each), and to plasmid vector cRNA 
(pGEM-4Z). A representative autoradiogram is presented from an experiment 
performed twice each with a different preparation of nuclei. 
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Table II. Regulation of gene transcription activity by insulin and pioglitazone-
induced differentiation of 3T3-F442A cells. 
EXP. 1 
cs INS PIO INS+PIO 
GLUT1 N.D. N.D. 10 N.D. 
GLUT4 N.D. 11 15 N.D. 
INS.REC. N.D. N.D. 27 N.D. 
ADIPSIN 208 152 255 142 
aP2 452 454 896 595 
EXP.2 
cs INS PIO INS+PIO 
GLUT1 N.D. N.D. 0.6 N.D. 
GLUT4 N.D. 57 N.D. N.D. 
INS.REC. N.D. N.D. N.D. N.D. 
ADIPSIN 181 125 131 108 
aP2 395 524 569 586 
Transcription run-on assay was carried out as described under figure 15. 
After hybridization and autoradiography, filters were cut and 32 P-labeled 
radioactivity hybridized to each cRNA was quantitated by scintillation counting. 
Data are expressed as count per minute ( cpm) after subtracting counts 
corresponding to vector-associatd radioactivity as background. N.D. indicates 
that signal was not detected. 
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Hfect d insulin and pioglitazone on mRNA stability 
Since observed increases in specific mRNA levels could not be explained by 
corresponding increases in their transcription rates, we investigated possible 
effects of insulin and pioglitazone on the stability of these mRNAs. 3T3-F442A 
cells were differentiated with insulin (1 µg/ml), pioglitazone (1 µM), or both for 
7 days. The transcription inhibitor agent, actinomycin D, was added at a final 
concentration of 5 µg/ ml to differentiated cells on day 7 or to undifferentiated 
control cells used just before reaching confluence (day 0), and total RNA was 
extracted from cells at indicated times after addition of the transcription 
inhibitor (0, 1, 2, 4, 6, 24 hr). The abundance of remaining mRNA transcripts 
for each gene was assessed on Northern blots. Differentiation of 3T3-F442A 
cells increased the GLUTl mRNA half life from about 2.2 hr in control 
undifferentiated cells to about 6.3, 4.1, and 24 hr in cells differentiated with 
insulin, pioglitazone, or both, respectively (Figure 16, Table III). The 
magnitude of GLUTl mRNA stabilization likely accounts for the previously 
described corresponding increases in GLUTl mRNA abundance. Similarly, 
GLUT4 mRNA half life increased from about 1.2 hr in undifferentiated control 
cells to about 20.2, 24, and > 24 hr in cells differentiated with insulin, 
pioglitazone, or both, respectively (Figure 17, Table III). Again, the magnitude 
of GLUT4 mRNA stabilization most likely accounts for described increases in 
mRNA abundance. Adipsin mRNA half life also increased from about 5.9 hr in 
control undifferentiated cells to more than 24 hr in cells differentiated with 
either insulin or pioglitazone or both (Figure 18, Table III), and this increase in 
half life could account for observed changes in mRNA abundance, except in the 
case of the combined treatment were the observed decrease in mRNA steady 
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state level could be due to transcriptional inhibition. On the other hand, there 
was no measurable change in mRNA stability for aP2 which showed half lives of 
more than 24 hr in control undifferentiated as well as differentiated cells 
(Figure 19, Table III). 
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Figure 16. Enhanced GLUTl mRNA stability by treatment with insulin, 
pioglitazone, or both. Confluent 3T3-F442A cells were differentiated with INS, 
PIO, or INS+ PIO for 7 days as described under materials and methods. On day 
7, the transcription inhibitor agent actinomycin D (Act D) was added to 
differentiated and undifferentiated (CS) control cells to a final concentration of 
5 µg/ ml and total RNA was extracted from cells at indicated time points (0, 1, 
2, 4, 6, 24 hr). Abundance of mRNA was assessed by Northern blotting analysis 
as described earlier. A, Quantitation of autoradiographic bands corresponding 
to the remaining GLUTl mRNA after Act D addition in undifferentiated and 
differentiated cells. Data are expressed as percent of mRNA remaining after 
Act D treatment relative to their levels before the treatment (time 0). Each 
data point represents mean values for n = 2 determinations. B, Blot showing 
remaining GLUTl mRNA after transcription inhibition in an experiment done 
in duplicate, except for the time "O" point of INS, where only a single sample is 
shown. Hours of film exposure were 40, 18, 24, and 8 hr for CS, INS, PIO, I+ P 
respectively. 
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Figure 17. Enhanced GLUT4 mRNA stability by treatment with insulin, 
pioglitazone, or both. Cell culture, differentiation, actinomycin D treatment, 
and mRNA analysis were done as described under figure 16. Data, which 
represent mean values for n = 2 determinations, are expressed as percent of 
mRNA remaining after Act D treatment relative to their levels at time 0. 
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Figure 18. Enhanced adipsin mRNA stability by treatment with insulin, 
pioglitazone, or both. Cell culture and differentiation, actinomycin D 
treatment, and mRNA analysis as described under figure 16. Data, which 
represent mean values for n = 2 determinations, are expressed as percent 
mRNA remaining after Act D treatment relative to their levels at time 0. 
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Figure 19. aP2 mRNA stability in undifferentiated and differentiated 3TI-
F442A cells. Cell culture, differentiation, actinomycin D treatment and mRNA 
analysis as described for figure 16. Data, which represent mean values for n = 2 
determinations, are expressed as percent of mRNA remaining after Act D 
treatment relative to their levels at time 0. 
Table III. Calculated mRNA half lives in hours for undifferentiated and 
differentiated 3T3-F442Acells. Data from actinomycin D (Act D) treatment 
experiment (Fig. 16, 17, 18, 19) were fitted to a single exponential decay curve 
by non linear least square regression analysis. The estimated first-order rate 
constant was used to calculate the mRNA half life. 
cs INS PIO INS+PIO 
GLUT1 2.2 6.3 4.1 > 24 
GLUT4 1.2 20.2 24 >24 
Adipsin 5.9 >24 >24 >24 
aP2 >24 >24 >24 >24 
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CHAPTERV 
DISCUSSION 
Hfect d insulin and pioglitaz.one on 3T3-F442A preadipocyte differentiation 
Pioglitazone, 5-[4-(2-(5-ethyl-pyridyl)ethoxy)-benzoyl]-2,4-thiazolidinedione, 
is an antidiabetic agent that has been shown to ameliorate hyperglycemia in 
animal models of non-insulin-dependent diabetes mellitus ( 6, 145, 159). 
Although a clear cut mode of action for pioglitazone has not been elucidated, 
this agent appears to potentiate insulin action both in vivo and in vitro as 
measured by enhanced insulin-stimulated glucose transport, suppressed 
hypertriglyceridemia and hyperinsulinemia, but without increasing insulin 
secretion (145,159). However, pioglitazone required the presence of insulin for 
these effects and did not change insulin binding, thus suggesting that it might act 
to amplify cellular responses to insulin. In fact, pioglitazone treatment was 
shown to increase insulin-stimulated autophosphorylation of insulin receptors in 
Wistar fatty rats (144), and to correct deficits in GLUT4 mRNA and protein in 
fat and muscle of insulin deficient rats and KKA Y obese mice ( 6). 
The purpose of my work was to further probe action mechanisms for 
pioglitazone. Since adipose tissue functions as an energy reservoir wherein 
glucose is used to synthesize triglycerides, treatment with agents such as 
pioglitazone, which enhance glucose uptake, would be expected to be associated 
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with changes in adipose tissue function and development. I thus decided to 
investigate the effect of pioglitazone treatment on the differentiation of 
preadipocytes to adipocytes as an indicator of adipose tissue development. 
Such differentiated adipocytes are known to be fully active in glucose uptake, 
storage, and metabolism. The results of this study clearly showed that the 
antidiabetic agent pioglitazone acts as a potent accelerator of adipocyte 
differentiation of 3T3-F442A cells. This was evidenced by the demonstration 
that treatment of fibroblast-like cells with pioglitazone led to acquisition of the 
morphological appearance of lipid-accumulating adipocytes with concomitant 
increases in triglyceride accumulation. Both insulin and pioglitazone acted 
synergistically on these parameters further supporting the notion that 
pioglitazone acts to amplify cellular responses to insulin. 
Although previous in vivo studies have shown the hypoglycemic effect of 
pioglitazone to be dependent upon the presence of circulating insulin, my study 
demonstrated effects of pioglitazone on cell differentiation without added 
insulin. These two observations however, would become consistent when we 
consider the fact that in my study differentiation was carried out in serum-
containing medium which is known to contain physiologically significant 
concentrations of insulin. Therefore, under my experimental conditions, 
pioglitazone might act to enhance cellular responses to low concentrations of 
insulin. 
Hfect d insulin and pioglitaznne on glucose transpoit activity and glucose 
transpoiter gene expression 
In the present study, I showed that the differentiation of 3T3-F442A cells 
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with insulin and pioglitazone was accompanied by concomitant increases in 
adipocyte basal glucose transport activity. Recent studies have established that 
facilitated diffusion of glucose across the plasma membrane of adipose cells is 
mediated by two glucose transporter proteins (105,106). Multiple mechanisms 
may exist by which hormones and other factors control the rate of glucose 
uptake across the plasma membrane. These include the rapid translocation of 
pre-existing transporters from intracellular pool to the plasma membrane, 
modulation of the intrinsic activity of pre-existing plasma membrane glucose 
transporters, and stimulation of the synthesis of new transporters (12). My 
results demonstrated increases in the expression of both GLUTl and GLUT4 
transporters on mRNA and protein levels. These results are in agreement with 
previous studies in which GLUTl and GLUT4 mRNA and protein levels were 
shown to increase during differentiation of 3T3 preadipose cells ( 61, 108). The 
increase in glucose transport activity in my study however, was at least an order 
of magnitude higher than the combined increase in both transporter proteins 
indicating that another mechanism such as increased transporter intrinsic 
activity may contribute to the observed effect. This is not an unusual 
observation since regulation of intrinsic transporter activity in 3T3-L 1 
adipocytes has been previously reported (160, 161). Inhibition of protein 
synthesis in 3T3-Ll adipocytes by anisomycin, for instance, appeared to 
stimulate glucose transport primarily by enhancing the intrinsic catalytic activity 
of cell surface GLUTl and to a lesser extent, GLUT4 proteins (161), while 
tumor necrosis factor-a treatment reportedly increased glucose transport and 
GLUTl transporter intrinsic activity in 3T3-Ll preadipose cells (160). 
87 
Although adipocyte differentiation by insulin or pioglitazone increased the 
expression of two transporter proteins and basal glucose uptake, no significant 
increase in insulin-responsiveness of differentiated cells was observed in the 
present study (data not shown). This could possibly be due to the chronic 
exposure of cells to low concentrations of insulin in the serum during 
differentiation, thus causing continuous translocation of existing, as well as 
newly synthesized transporters, into the plasma membrane further contributing 
to the high level of basal glucose uptake. Consequently, acute insulin exposure 
does not induce further translocation normally known to be responsible for 
enhanced acute insulin- responsiveness. Consistent with that mechanism are 
two observations established by previous studies. First, chronic exposure of 
differentiated 3T3-Ll adipocytes to insulin has been shown to result in 
persistent state of enhanced basal glucose transport activity which was resistant 
to further stimulation by insulin during hexose uptake assays ( 45), and second, 
chronic insulin treatment of 3T3-F442A (108) and 3T3-Ll (62) adipocytes 
induced a redistribution of glucose transporters in these cells from plasma 
membrane to low density microsomes which was associated with marked 
resistance of cells to restimulate glucose transport and particularly to recruit 
GLUT4 to the cell surface following an additional insulin treatment (62). The 
first study showed that chronic insulin treatment increased total cellular 
GLUTl but did not change total cellular GLUT4 ( 45), while the latter study 
showed that insulin resistance was associated with selective down-regulation of 
cell-surface GLUT4 glucose transporter and particularly with a marked 
resistance of cells to further recruit GLUT4 to the cell-surface following an 
additional insulin treatment; while levels of GLUTl at the surface were 
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markedly increased ( 62). These observations are in contrast with results 
reported in another study in which insulin sensitivity was shown to increase 
during differentiation of 3T3-L1 cells (61). In that study however, adipocyte 
differentiation was induced by insulin, dexamethasone, and 
isobutylmethylxanthine (IBMX), all of which are independently known to 
regulate glucose transport and glucose transporter activity. Indeed, a similar 
study showed that basal glucose uptake in 3T3-L 1 adipocytes was 50% lower 
than that in fibroblasts which was due to more than 90% inhibition of the 
intrinsic catalytic activity of GLUTl on the surface of mouse 3T3-L 1 adipocytes 
(162). Therefore, a mechanism that markedly suppressed basal glucose 
transport catalyzed by GLUTl was implicated as the major contributor to the 
dramatic insulin sensitivity of glucose uptake in 3T3-L 1 adipocytes in these 
studies. Thus, elevated basal glucose transport activity in my study would be 
consistent with continuous translocation of existing, as well as newly 
synthesized, GLUTl transporter into the cell-surface. In addition, changes in 
intrinsic activity of cell-surface transporters would be speculated to account for 
any discrepancy between increased GLUTl expression and increased basal 
glucose uptake activity. Although there is an apparent contradiction between 
increased GLUT4 expression and cell unresponsiveness, these two observations 
are consistent with increased GLUT4 expression due to the differentiation of 
preadipocytes to adipocytes, and with cell inability to recruit GLUT4 to the cell-
surface due to the continuous exposure to insulin during differentiation. 
Hfects d insulin and pioglitazone on adipocyte-specific gene expression 
The present study indicated that the effect of insulin and pioglitazone on 
gene expression was not glucose transporter-specific since the abundance of 
mRNAs encoding other adipocyte-specific genes were increased at the same 
time, further confirming that pioglitazone has a general differentiation effect. 
Adipsin and aP2 mRNAs for instance, were both increased by insulin or 
pioglitazone treatments, in agreement with earlier studies in which these two 
mRNA transcripts were shown to increase during adipocyte differentiation 
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(8, 10,85,92,99). No significant effect on insulin receptor gene expression was 
detectable in my experiments under the same condition despite the fact that its 
message and protein product have previously been reported to increase during 
3T3-L 1 adipocyte differentiation ( 44,57,59,60, 102). The disparity between my 
present results and those reported in previous studies could be due to the use of 
different cell lines and/ or different differentiation conditions. In all these 
studies, the 3T3-L1 preadipocyte/adipocyte cell line was used as a model 
system. In addition, their differentiation medium variously contained 
dexamethasone, IBMX, insulin, and indomethasone, all of which are known to 
regulate adipocyte differentiation ( 44,57,59,60). My results also showed that 
cell differentiation induced by a combination of insulin and pioglitazone 
completely inhibited adipsin mRNA expression. Such results implicate some 
negative mechanism contributing to the observed down-regulation effect on 
adipsin and insulin receptor genes. In fact, prolonged insulin treatment has 
previously been shown to downregulate insulin receptor protein and mRNA in 
various tissues by accelerating its degradation and decreasing its biosynthesis 
(58). Insulin was also shown to exert negative effect on the abundance of 
adipsin mRNA in differentiating, as well as in fully differentiated 3T3-F442A 
adipocytes via a mechanism which involved primarily a rapid inhibition of the 
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transcriptional rate (73, 100, 163). Thus, it appears that insulin has both positive 
effects due to its ability to accelerate differentiation, and negative effects due to 
direct down-regulation at different pre-translational and/ or post-translational 
levels, on insulin receptor and adipsin mRNAs. Indeed, my results 
demonstrated that insulin and pioglitazone withdrawal after differentiation 
relieved the negative down-regulating effect, thus revealing the differentiation-
dependent increases for these two mRNAs. The fact that insulin completely 
down-regulated adipsin mRNA only in the presence of pioglitazone provides 
additional evidence that pioglitazone acts to amplify cellular responses to 
insulin. 
Hfect d insulin and pioglitazone on transcription activity and mRNA stabi1ity 
It has been previously established that alternations in the steady state level 
of several mRNAs during differentiation were accompanied by activation of 
specific gene transcription (8-10,75). This was particularly shown for mRNAs 
whose abundance is dramatically increased (20- to 100-fold) during 
differentiation, including the aP2 and glycerolphosphate dehydrogenase genes. 
These same studies showed no significant change in the rates of transcription of 
mRNAs whose abundance was only moderately altered (2- to 4-fold) during 
differentiation, such as those encoding fructose-1,6-bisphosphate, B-actin, a-
actin, and B-tubulin (8). While transcriptional activation of adipsin gene 
expression during 3T3-F442A differentiation was reported in one study (9), 
another study failed to show such activation for this gene under similar 
conditions (10). In these studies however, aP2 and adipsin mRNAs were found 
to be far more abundant than would be predicted by their nuclear transcription 
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alone, suggesting that other levels of control may contribute to the relative 
abundance of these mRNAs. In my present study, run-on transcription by 
nuclei isolated from undifferentiated 3T3-F442A cells or from cells 
differentiated with insulin and/ or pioglitazone revealed little or no change in 
the transcription activity for all studied genes. No transcription signal could be 
detected for GLUT1 and GLUT4 mRNAs in either undifferentiated or 
differentiated cells, although both mRNAs increased in abundance moderately 
(2- to 6-fold) during differentiation. Transcription of adipsin and aP2 was 
strongly detectable in undifferentiated cells, but no significant change in their 
transcription activity could be detected upon differentiation despite the 
dramatic increase (20- to 70-fold) in their steady state levels. There were two 
exceptions. Insulin, in combination with pioglitazone, decreased the 
transcription of adipsin mRNA, while pioglitazone moderately increased ( < 2-
fold) the transcription of aP2 mRNA. In all cases, the increase in the steady 
state level of all studied mRNAs could not be explained by changes in their 
corresponding transcription activities suggesting that other levels of control, 
possibly mRNA stability, may contribute to the relative abundance of certain 
mRNAs during adipocyte differentiation. To further investigate such a 
possibility, I compared mRNA half lives in undifferentiated and differentiated 
cells. Differentiation of 3T3-F442A cells by insulin and/ or pioglitazone 
increased the mRNA half lives for GLUTl, GLUT4, and adipsin above their 
values in undifferentiated cells. Furthermore, the stabilization of these mRNAs 
caused by differentiation appears to fully account for the increase in their steady 
state levels under most of the treatment conditions. There has been no 
correlation, however, between the increase in adipsin mRNA half life and its 
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steady state levels in the combined insulin and pioglitazone treatment. In this 
case, the observed inhibition of gene transcription activity may account for the 
extremely low abundance of adipsin mRNA. My results also failed to explain 
the dramatic induction of aP2 gene expression upon differentiation, since its 
mRNA was apparently very stable (half-life > 24 hr) in both undifferentiated 
and differentiated cells. This could be due to several reasons. First, RNA 
extracted from undifferentiated cells may has been contaminated with RNA 
from a small number of spontaneously-differentiating cells in the same culture. 
Thus, if aP2 gene expression is greatly enhanced very early in the process, My 
results would falsely indicate very stable mRNA in undifferentiated cells. 
Although I purposely used undifferentiated cultures before they reached 
confluence, such spontaneous cell differentiation is still possible. Thus, further 
in ·situ hybridization experiments would be required to confirm whether their is 
an expression of aP2 gene in a minor population of spontaneously 
differentiating fibroblast cells. An alternate possibility is that another post-
transcriptional step, such as RNA processing contributes to the accumulation of 
aP2 mRNA during differentiation. Since Northern blots showed only a single 
aP2 mRNA species of the same size in both undifferentiated and differentiated 
cells, such RNA processing would have to occur very early and extremely fast 
during differentiation to explain our ability to detect a presumably processed 
aP2 mRNA in undifferentiated cells. Another possibility is that aP2 mRNA is 
stable in undifferentiated cells (half life > 24 hr) and it becomes more stable 
with differentiation, but my results showed no measurable change in half life 
because we carried out the stability study for only 24 hours. Measurements of 
the aP2 mRNA half life, or that of any other adipocyte-specific mRNA, in 
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undifferentiated preadipocytes have not been reported before because of the 
extremely low abundance of the RNA in these cells. One study however, 
reported aP2 mRNA half life in differentiated adipocytes and found it to be far 
more stable in the adipocyte cytoplasm than other mRNAs examined, with an 
estimated half life of 12 hours (10). Since that study did not show aP2 mRNA 
half life in preadipocytes, it failed to indicate whether the apparent stability of 
the aP2 is dependent on differentiation or whether it is an intrinsic property of 
the RNA molecule. In either case, my results showed far more stable mRNA 
( > 24 hr) than was reported which leads to another possibility. Actinomycin D 
treatment has been shown specifically to stabilize certain mRNAs. For 
instance, actinomycin D has been reported to have stabilizing effect on mRN As 
for all protein kinase A subunits (164). Since aP2 mRNA half life in adipocytes 
was reported to be 12 hours using 5,6-dichloro-1-.B-D-
ribofuranosylbenzimidazole (DRB) as a transcription inhibitor, the apparent 
stability of aP2 mRNA in undifferentiated and differentiated cells in my study 
could be due to a direct stabilizing effect on the aP2 gene by actinomycin D 
treatment. This issue would be resolved in future studies by using a different 
transcription inhibitor such as DRB, or thiolutin, or using a different method 
such as [3H]uridine-chase method to assess message stability. 
Taken together, my results indicate that the mechanism underlying 
differentiation-dependent changes in mRNA abundance induced by insulin or 
pioglitazone appears to be mostly on the level of mRNA stability rather than 
transcriptional activation. Although this is the first study that directly shows 
increased mRNA abundance during differentiation by increasing message 
stability, such mechanism of regulation at mRNA stability level has been 
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reported under various conditions. Treatment of 3T3-F442A mature adipocytes 
with retinoic acid for instance, specifically decreased the adipsin mRNA level 
(165). The rate of adipsin gene transcription remained unchanged, while the 
half life of adipsin mRNA was greatly shortened in retinoic acid-treated 
adipocytes (37.6 to 7.3 hr) as compared with untreated cells. Another example 
is the induction of GLUTl, as well as other immediate early growth related 
protooncogenes, in 3T3-Ll fibroblasts by treatment with tumor necrosis factor-
a (160,166) and 8-bromo-cAMP (167). While transcriptional activation of 
immediate-early genes correlated well with subsequent accumulation of their 
respective mRNAs, increased GLUTl mRNA was due to apparent increase in 
the stability of this message ( 45 min to several hours) and not to increased 
transcription. Another study showed that increased GLUTl mRNA abundance 
by chronic exposure of L6 myocytes to insulin was due to increased transcription 
as well as prolonged half life (2-2.5 hr to 5 hr) (168). 
Signfficance and future studies 
My findings demonstrated that pioglitazone, like insulin, has the ability to 
accelerate the in vitro adipocyte differentiation of 3T3-F442A cells with 
concomitant increases in the expression of two glucose transporter genes. This 
finding is consistent with a recent report of pioglitazone having adipogenic 
activity in 3T3-Ll cell line (169). This is the second example of an antidiabetic 
agent with adipogenic activity. A recent study demonstrated that another 
antidiabetic agent with similar thiazolidinedione derived structure, AD4 7 43, 
enhanced adipocyte differentiation of 3T3 T mesenchymal stem cells (77). 
Although not established in vivo, this would constitute an interesting mechanism 
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of action for hypoglycemic agents by enhancing insulin sensitivity of target 
tissues, thus correcting blood glucose levels in diabetes. Therefore, the effect of 
pioglitazone on adipocyte differentiation from stromal vascular cells (the in vivo 
adipocyte progenitor cell) should be investigated and characterized in future 
experiments to establish the pertinence of such an effect to its in vivo 
hypoglycemic activity. The observations that pioglitazone acted synergistically 
with insulin on adipocyte differentiation and on glucose transport activity 
provide additional support to the concept that pioglitazone acts to amplify 
cellular responses to insulin, but do not prove it. Since cell differentiation was 
carried out in the presence of serum, I was not able to ascertain whether 
pioglitazone induced effects on cell differentiation and glucose transport activity 
were dependent on the presence of insulin in the serum or not. Thus, it is 
necessary to develop a defined serum-free differentiation medium in order to 
determine the role of each of insulin and pioglitazone individually and how they 
interact with each other to regulate adipocyte differentiation and glucose 
transport activity. 
Pioglitazone also showed direct transcriptional activation effect on the aP2 
gene. Considering the fact that aP2 mRNA is expressed at high levels in 
adipocytes (87), and that it has a postulated role as a mediator of insulin actions 
(89), aP2 presents an interesting candidate gene for further exploration of 
insulin action mechanisms, their perturbations in diabetes, and possible 
corrective effects of pioglitazone treatment. 
My findings have interesting implications for better understanding the 
processes involved in cellular differentiation and development. This is the first 
report directly showing increased abundance of adipocyte-specific mRNA 
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during differentiation as result of increasing message stability, although the 
concept was previously inferred (8-10). The stabilization or destabilization of 
mRN As in response to some biological or pharmacological stimuli has been 
recognized as an important post-transcriptional step in the regulation of gene 
expression (170-173). Despite that, the mechanism underlying such processes, 
including the signals that trigger mRNA degradation, the structural elements of 
an individual mRNA recognized by the degradative enzymes, as well as the 
enzymes and other trans-acting factors that are involved in mRNA degradation, 
remain largely unknown (170,173-176). 
Recent studies demonstrated that some mRNA sequences may play 
important role in determining degradation rates. Of particular importance are 
the 3' terminal untranslated region (UTR) and poly(A) sequences (174). The 
rate of mRNA degradation was shown to be dependent on the presence or 
absence of the 3' terminal poly(A), and that the de-adenylated mRNA 
apparently had a faster rate of turnover ( 170, 177, 178). 
Although not studied within the context of differentiation, there is some 
evidence that adipsin and GLUTl mRNAs are regulated through effects on 
their 3' -UTR sequences. A recent study has shown that within a physiological 
range of concentrations, insulin exerts a negative effect on adipsin mRNA 
abundance in 3T3-F442A adipocytes, which was found to involve a rapid 
inhibition of the transcriptional rate (163). At the same time, insulin showed a 
specific effect on the length of the poly( A) tract of the adipsin mRNA. The 
study did not show the consequence of decreasing the adipsin poly(A) tract 
length, but speculated that it could affect translational efficiency or the stability 
of mRNA. Indeed, upon examining my Northern blots carefully, both GLUTl 
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and adipsin mRNAs appeared as broad signals in differentiated cells. Such 
heterogeneity in mRNA length could be speculated to be the result of variation 
of the poly( A) tract length which would be consistent with the previously cited 
study (163). Further experiments using RNase H digestion of mRNA would be 
required to prove such a possibility. 
Another study showed that tumor necrosis factor-a stimulated hexose 
transport in quiescent 3T3-Ll preadipocytes by stabilizing the relatively labile 
mRNA coding for the basal glucose transporter, GLUTl (166). The 3'-UTR of 
GLUTl mRNA contains a single copy of the destabilizing AUUUA motif in the 
context of an AU-rich region. The stability of GLUTl mRNA was found to be 
partially controlled by its interaction with sequence-specific mRNA binding 
protein, the adenosine-uridine binding factor (AUBF), which was speculated to 
mediate mRNA stabilization by blocking the AU-destabilizing motifs. Further 
sequence analysis of the 3' -UTR of other adipocyte-specific genes is required to 
identify putative cis'-elements through which such regulation might occur. 
Thus, increasing mRNA abundance during differentiation by increasing 
message stability presents an interesting phenomenon awaiting further probing 
with regard to the differentiation and development fields. Future efforts should 
be particularly directed towards identifying common mRNA sequences that may 
function as stabilizing elements in the differentiation-induced mRNAs, and the 
potential regulatory mRNA binding proteins that are upregulated in response to 
various differentiation-inducing factors. 
Overall, this study of pioglitazone effects in a cell culture system should 
prove to be a useful model with which to study molecular mechanisms 
underlying cell differentiation as well as insulin action on glucose transport. 
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